[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 36736
1. Lemez P, Attarbaschi A, Béné MC, Bertrand Y, Castoldi G, Forestier E, Garand R, Haas OA, Kagialis-Girard S, Ludwig WD, Matutes E, Mejstríková E, Pages MP, Pickl W, Porwit A, Orfao A, Schabath R, Starý J, Strobl H, Talmant P, van't Veer MB, Zemanová Z, European Group for the Immunological Characterization of Leukemias (EGIL): Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases. Eur J Haematol; 2010 Oct;85(4):300-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases.
  • OBJECTIVES: Patients with near-tetraploid (karyotype: 81 - 103 chromosomes) acute lymphoblastic leukemia (NT-ALL) constitute about 1% of childhood ALL and data reported on them are limited and controversial.
  • METHODS: The members of the European Group for Immunophenotyping of Leukemias (EGIL) searched retrospectively their databases for NT-ALL patients.
  • Ten children were diagnosed as T-cell ALL (T-ALL) EGIL categories (T-I n=2, T-II n=2, T-III n=3, T-IV n=3) and four displayed various structural chromosomal abnormalities.
  • B-cell precursor (BCP) ALL was diagnosed in 26 children.
  • One girl with hypodiploid and NT metaphases and ETV6-RUNX1-negative BCP-ALL and one of two boys with NT-BCP-ALL not examined for ETV6-RUNX1 died of infection after stem cell transplantation in 2nd/3rd CR.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20561032.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


2. Szmyd K, Chaber R, Fiszer-Maliszewska L, Reich A, Grotthus E, Weclawek-Tompol J, Chybicka A: [Mean level of expression of c-myb gene in leukaemia of children]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):587-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mean level of expression of c-myb gene in leukaemia of children].
  • AIM OF THE STUDY: Measurement of c-myb expression in leukaemia cells in children and in normal cells of healthy controls.
  • MATERIAL AND METHODS: 37 patients, 23 boys and 14 girls with acute leukaemia, aged 1-17 years, were included in the study (32 with acute lymphoblastic leukaemia and 5 with acute myeloblasts leukaemia) Control group consisted of 17 healthy children, 8 boys and 9 girls, 4-18 years old.
  • RESULTS: Mean level of expression of c-myb gene in leukaemia cells was statistically significantly higher than in the control group (0.71+/-0.53 vs. 0.51+/-0.22; p=0.05), as well as c-myb level between leukaemia cells in relapse cases and controls (0.83+/-0.23 vs. 0.51+/-0.22; p=0.01).
  • There was no difference between c-myb expression in different diagnosis.
  • CONCLUSIONS: Possible influence of increased expression of c-myb gene in the promotion of leukaemia was found.
  • The role of c-myb expression as a prognostic factor in acute leukaemias of children was not confirmed.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-myb / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317889.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myb
  •  go-up   go-down


3. Li YN, Zou DH, Gu M, Mi YC, Wang JX, Qiu LG: [The role of BCR/ABL isoforms in the presentations and outcome of Philadelphia-positive acute lymphoblastic leukemia in adult patients]. Zhonghua Nei Ke Za Zhi; 2009 Jun;48(6):481-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of BCR/ABL isoforms in the presentations and outcome of Philadelphia-positive acute lymphoblastic leukemia in adult patients].
  • OBJECTIVE: To investigate the difference of clinical characteristics and outcomes between different isoforms of BCR/ABL in adults with Philadelphia-positive acute lymphoblastic leukemia (ALL).
  • RESULTS: The median age of the 106 patients was 34 years and the median white blood cell count at baseline was 28.5 x 10(9)/L.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954044.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / abl-bcr fusion protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


Advertisement
4. Adam de Beaumais T, Dervieux T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, Jacqz-Aigrain E: The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol; 2010 Sep;66(4):653-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
  • PURPOSE: Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN).
  • [MeSH-major] 6-Mercaptopurine / pharmacokinetics. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / pharmacokinetics. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033410.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; FTK8U1GZNX / Thioguanine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, Blaise D, Rocha V, Acute Leukemia Working Party, European Group for Blood and Marrow Transplantation: Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica; 2008 Feb;93(2):303-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
  • This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation.
  • With a median follow-up of 2.8 years, two year overall-survival, leukemia-free survival and non-relapse mortality were significantly better in patients transplanted in first complete remission (CR1, 52+/-9%; 42+/-10%; and 18+/-7% respectively) compared with those transplanted in more advanced phase (p=0.003, p=0.002 and p=0.01 respectively).
  • In multivariate analysis, disease status (CR1 vs. advanced; p=0.001) and chronic graft-vs-host disease (p=0.01) were associated with an improved overall-survival, suggesting that reduced-intensity conditioning allogeneic stem cell transplantation is feasible in patients with high risk lymphoblastic leukemia in remission at transplantation.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Disease-Free Survival. Europe. Female. Follow-Up Studies. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous


6. Martin MB, Li CS, Rowland CC, Howard SC, Kaste SC: Correlation of bone age, dental age, and chronological age in survivors of childhood acute lymphoblastic leukaemia. Int J Paediatr Dent; 2008 May;18(3):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of bone age, dental age, and chronological age in survivors of childhood acute lymphoblastic leukaemia.
  • BACKGROUND: There is little information about oncotherapy-related dental development in childhood acute lymphoblastic leukaemia (ALL).
  • The cohort was divided into three categories based on age at diagnosis (< 6 years, 6-9 years, > 9 years).
  • Median CA at diagnosis was 4.5 years (range: 0.1-11.0 years); time to study was 4.1 years (range: 0.3-11.4 years).
  • [MeSH-major] Age Determination by Skeleton. Age Determination by Teeth. Child Development. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Child Development.
  • MedlinePlus Health Information. consumer health - Infant and Newborn Development.
  • MedlinePlus Health Information. consumer health - Toddler Development.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298546.001).
  • [ISSN] 1365-263X
  • [Journal-full-title] International journal of paediatric dentistry
  • [ISO-abbreviation] Int J Paediatr Dent
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Zunino SJ, Storms DH, Ducore JM: Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11). Int J Oncol; 2010 Nov;37(5):1307-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11).
  • We evaluated the cell cycle status and the phosphorylation/activation of proteins involved in signal transduction in t(4;11) and non-t(4;11) acute lymphoblastic leukemia (ALL) cell lines after treatment with parthenolide.
  • These data show that parthenolide induces a stress response leading to cell death and provide further evidence suggesting that parthenolide could be useful as a novel therapeutic agent against high risk ALL with chromosomal translocation t(4;11).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 4 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sesquiterpenes / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Cell Separation. Flow Cytometry. Humans. Signal Transduction / drug effects. Translocation, Genetic


8. Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, Kasai M, Kakinoki Y, Masauzi N, Morioka M, Kawamura T, Iwasaki H, Asaka M, Imamura M: Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Am J Hematol; 2005 Nov;80(3):181-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
  • We evaluate whether molecular monitoring of minimal residual disease (MRD) using TCR delta (TCRD), TCR gamma (TCRG), and immunoglobulin H (IgH) gene rearrangements in the bone marrow (BM) is correlated with clinical events in ALL patients.
  • The median WBC count was 11.3 x 10(9)/L at diagnosis.
  • Event-free survival (EFS, 0%) and disease-free survival (DFS, 0%) at 1 year in CR patients with MRD level >or=10(-3) (n = 3) were significantly lower than those in CR patients with MRD level <10(-3) (n = 6) (log-rank test, P = 0.013, 0.013).
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, T-Lymphocyte. Immunoglobulin Heavy Chains / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Clone Cells. Female. Follow-Up Studies. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Male. Middle Aged. Molecular Diagnostic Techniques. Neoplasm, Residual / diagnosis. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247752.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


9. Foster M: Sports dentistry--what's it all about? SADJ; 2009 Jun;64(5):198, 200-2, 204 passim
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CLINICAL RELEVANCE: The early diagnosis and management of dental conditions that affect athletes will ensure sound dental health is preserved for these high risk patients.
  • The clinician needs to be aware of a variety of dental conditions that can prevent significant dental trauma and acute manifestations at the time of competition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] Dent Update. 2009 Apr;36(3):135-8, 141-4 [19480101.001]
  • (PMID = 19725331.001).
  • [ISSN] 1029-4864
  • [Journal-full-title] SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging
  • [ISO-abbreviation] SADJ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


10. Griffioen M, Kessler JH, Borghi M, van Soest RA, van der Minne CE, Nouta J, van der Burg SH, Medema JP, Schrier PI, Falkenburg JH, Osanto S, Melief CJ: Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res; 2006 May 15;12(10):3130-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
  • PURPOSE: Preferentially expressed antigen on melanomas (PRAME) is an interesting antigen for T-cell therapy because it is frequently expressed in melanomas (95%) and other tumor types.
  • Moreover, due to its role in oncogenic transformation, PRAME-negative tumor cells are not expected to easily arise and escape from T-cell immunity.
  • The purpose of this study is to investigate the usefulness of PRAME as target for anticancer T-cell therapies.
  • EXPERIMENTAL DESIGN: HLA-A*0201-subtyped healthy individuals and advanced melanoma patients were screened for CD8+ T cells directed against previously identified HLA-A*0201-binding PRAME peptides by IFN-gamma enzyme-linked immunosorbent spot assays and tetramer staining.
  • PRAME-specific T-cell clones were isolated and tested for recognition of melanoma and acute lymphoid leukemia (ALL) cell lines.
  • PRA(100-108)-tetramer+ T-cell clones were shown to recognize and lyse HLA-A*0201+ and PRAME+ melanoma but not ALL cell lines.
  • Quantitative real-time reverse transcription-PCR showed significantly lower PRAME mRNA levels in ALL than in melanoma cell lines, suggesting that PRAME expression in ALL is below the recognition threshold of our PRA(100-108)-tetramer+ T cells.
  • CONCLUSION: These data support the usefulness of PRAME and in particular the PRA(100-108) epitope as target for T-cell therapy of PRAME-overexpressing cancers.
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Epitopes. HLA-A Antigens / immunology. HLA-A2 Antigen. Humans. Immunotherapy / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707612.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / PRAME protein, human
  •  go-up   go-down


11. Zhao X, Tang KJ, Tian Z, Chen LP, Mi YC, Wang JX: [FLT3 mutation in patients with acute lymphoblastic leukemia and its clinical significance]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct;31(5):522-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FLT3 mutation in patients with acute lymphoblastic leukemia and its clinical significance].
  • OBJECTIVE: To investigate fms-like tyrosine kinase 3 (FLT3) mutation in patients with acute lymphoblastic leukemia (ALL) and its clinical significance.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968062.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


12. Boccon-Gibod L, Boman F, Josset P, Landman-Parker J: Mucoepidermoid carcinoma of the parotid gland in a child previously treated for acute lymphoblastic leukemia. Pediatr Blood Cancer; 2005 Jun 15;44(7):673-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the parotid gland in a child previously treated for acute lymphoblastic leukemia.
  • Children treated for acute lymphoblastic leukemia (ALL) have an increased risk for developing mucoepidermoid carcinomas (MEC) of the parotid gland.
  • This case report is remarkable for the early diagnosis of second cancer, only 4 years after diagnosis of ALL, and its occurrence in parotid gland without previous head and neck irradiation.
  • [MeSH-major] Carcinoma, Mucoepidermoid / etiology. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15515042.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


13. Choi WH, Choi BR, Kim JH, Yeo WS, Oh S, Kim DE: Design and kinetic analysis of hammerhead ribozyme and DNAzyme that specifically cleave TEL-AML1 chimeric mRNA. Biochem Biophys Res Commun; 2008 Sep 12;374(1):169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to develop the oligonucleotides to abolish an expression of TEL-AML1 chimeric RNA, which is a genetic aberration that causes the acute lymphoblastic leukemia (ALL), hammerhead ribozymes and deoxyoligoribozymes that can specifically cleave TEL-AML1 fusion RNA were designed.
  • [MeSH-minor] Catalysis. Cell Line, Tumor. Gene Transfer Techniques. Humans. Kinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18627769.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA, Catalytic; 0 / Oligonucleotides; 0 / Oncogene Proteins, Fusion; 0 / RNA, Catalytic; 0 / RNA, Messenger; 0 / TEL-AML1 fusion protein; 0 / hammerhead ribozyme
  •  go-up   go-down


14. He YL, Li CF, Shi L: [High dose methotrexate induced acute renal insufficiency in a patient with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2007 Jan;45(1):78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High dose methotrexate induced acute renal insufficiency in a patient with acute lymphoblastic leukemia].
  • [MeSH-major] Acute Kidney Injury / chemically induced. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349162.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Janiszewska H, Styczynski J, Kolodziej B, Wysocki M, Haus O: Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia. Ann Hematol; 2009 Dec;88(12):1193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia.
  • Multidrug resistance 1 (MDR1) gene expression determined by real-time polymerase chain reaction and results of rhodamine assay were analyzed at diagnosis and after 3 days of ex vivo therapy with prednisolone in 36 pediatric patients with acute lymphoblastic leukemia (ALL).
  • Only 62% patients with de novo ALL had significant decrease of MDR1 expression.
  • These patients had over twofold lower rhodamine retention in the presence of cyclosporine A on day 3 than others and had better probability of disease-free survival.
  • In this study, we have shown that changes in the expression of MDR1 gene after short-term incubation of lymphoblasts with prednisolone may have prognostic value in pediatric de novo ALL patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Gene Expression Regulation, Neoplastic. P-Glycoprotein. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisolone / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Drug Resistance, Neoplasm / genetics. Female. Humans. Infant. Male. P-Glycoproteins. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352661.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents, Hormonal; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


16. Withycombe JS, Post-White JE, Meza JL, Hawks RG, Smith LM, Sacks N, Seibel NL: Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. Pediatr Blood Cancer; 2009 Dec 15;53(7):1249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This retrospective analysis defined and described patterns and predictors of weight change during treatment in children with acute lymphocytic leukemia (ALL) with high-risk features who received treatment on Children's Cancer Group protocol CCG 1961.
  • RESULTS: By the end of treatment, 23% of children were obese (BMI >or=95%), compared with 14% at diagnosis.
  • Children who were of Black or Hispanic race, obese at diagnosis, or who had grade 3 or 4 pancreatitis/glucose toxicities during induction had higher BMI% throughout treatment.
  • Children were more likely to be obese at the end of the study if they were aged 5-9 years at diagnosis or female gender.
  • The beginning of maintenance therapy may be the best time to intervene with nutritional and behavioral interventions, particularly for children who are obese or aged 5-9 years at diagnosis, female, Black or Hispanic, or those with metabolic toxicities during induction.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3742-5 [11502805.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):557-68 [12754700.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2953-60 [12885815.001]
  • [Cites] Pediatrics. 2003 Aug;112(2):424-30 [12897303.001]
  • [Cites] Arch Dis Child. 2003 Sep;88(9):748-52 [12937090.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Oct;27(10):1141-51 [14513062.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26 [15087948.001]
  • [Cites] Arch Dis Child. 1994 Aug;71(2):147-9 [7944537.001]
  • [Cites] J Pediatr. 1995 Jul;127(1):63-7 [7608813.001]
  • [Cites] Pediatr Res. 1995 Jul;38(1):86-90 [7478803.001]
  • [Cites] Stat Med. 1997 Aug 30;16(16):1859-71 [9280038.001]
  • [Cites] Int J Cancer Suppl. 1998;11:81-4 [9876486.001]
  • [Cites] Eur J Clin Nutr. 2005 Mar;59(3):419-25 [15674315.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1725-9 [15754333.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1730-9 [15761876.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):881-91 [16035086.001]
  • [Cites] Am J Clin Nutr. 2006 Jan;83(1):70-4 [16400052.001]
  • [Cites] J Pediatr Oncol Nurs. 2006 May-Jun;23(3):135-42 [16624889.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1183-9 [17401007.001]
  • [Cites] Psychooncology. 2007 May;16(5):448-57 [16915562.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2063-9 [17513811.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Apr-May;17(3):231-7 [10779989.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • (PMID = 19688832.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01; United States / NCI NIH HHS / CA / U10CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS144355; NLM/ PMC3044478
  •  go-up   go-down


17. Cooley LD, Chenevert S, Shuster JJ, Johnston DA, Mahoney DH, Carroll AJ, Devidas M, Linda SB, Lauer SJ, Camitta BM: Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Cancer Genet Cytogenet; 2007 Jun;175(2):117-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
  • Chromosome anomalies have been shown to have prognostic significance in children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 21 / genetics. Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17556067.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA030969; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P, Micalizzi C, Buffardi S, Basso G, Zanesco L, Rosolen A: Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. J Clin Oncol; 2007 Nov 20;25(33):5254-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
  • PURPOSE: To study the prevalence of t(8;14) at diagnosis and the response kinetics to treatment of minimal residual disease (MRD) in B-cell acute lymphoblastic leukemia (B-ALL) patients and determine its impact on prognosis.
  • PATIENTS AND METHODS: A total of 68 children affected by de novo B-ALL enrolled onto the Berlin-Frankfurt-Muenster-based Italian Association of Pediatric Hematology and Oncology LNH-97 clinical protocol were studied.
  • Bone marrow aspirate from each patient was analyzed for the presence of t(8;14)(q24;q32) by long-distance polymerase chain reaction at diagnosis, after the first chemotherapy cycle, and after subsequent cycles until negative for MRD.
  • Morphologic and immunophenotypic analyses were reviewed centrally.
  • [MeSH-major] Burkitt Lymphoma / mortality. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024872.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


19. Chong SC, Joo SJ, Emmanouil TA, Treisman A: Statistical processing: not so implausible after all. Percept Psychophys; 2008 Oct;70(7):1327-34; discussion 1335-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical processing: not so implausible after all.
  • Myczek and Simons (2008) have shown that findings attributed to a statistical mode of perceptual processing can, instead, be explained by focused attention to samples of just a few items.
  • Some new findings raise questions about this claim. (1) Participants, given conditions that would require different focused attention strategies, did no worse when the conditions were randomly mixed than when they were blocked. (2) Participants were significantly worse at estimating the mean size when given small samples than when given the whole display. (3) One plausible suggested strategy--comparing the largest item in each display, rather than the mean size--was not, in fact, used.
  • Distributed attention to sets of similar stimuli, enabling a statistical-processing mode, provides a coherent account of these and other phenomena.
  • [MeSH-major] Cognition. Data Interpretation, Statistical
  • [MeSH-minor] Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Percept Psychophys. 2008 Jul;70(5):772-88 [18613626.001]
  • (PMID = 18927015.001).
  • [ISSN] 0031-5117
  • [Journal-full-title] Perception & psychophysics
  • [ISO-abbreviation] Percept Psychophys
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 2R01 MH 058383-04A1
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Pérez-Gómez J, Moore I: Plant endocytosis: it is clathrin after all. Curr Biol; 2007 Mar 20;17(6):R217-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plant endocytosis: it is clathrin after all.
  • Endocytosis occurs in plants, but the involvement of clathrin-coated vesicles has been unclear; a new study provides strong evidence that, as in animal cells, clathrin-coated vesicles are a major means of internalisation by plant cells.
  • [MeSH-major] Arabidopsis / metabolism. Clathrin / physiology. Clathrin-Coated Vesicles / physiology. Endocytosis / physiology
  • [MeSH-minor] Protoplasts / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Curr Biol. 2007 Mar 20;17(6):520-7 [17306539.001]
  • (PMID = 17371763.001).
  • [ISSN] 0960-9822
  • [Journal-full-title] Current biology : CB
  • [ISO-abbreviation] Curr. Biol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BBS/B/09562
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Clathrin
  •  go-up   go-down


21. Virely C, Moulin S, Cobaleda C, Lasgi C, Alberdi A, Soulier J, Sigaux F, Chan S, Kastner P, Ghysdael J: Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia; 2010 Jun;24(6):1200-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.
  • [MeSH-major] Fusion Proteins, bcr-abl / physiology. Genes, Tumor Suppressor / physiology. Ikaros Transcription Factor / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


22. Akahane K, Inukai T, Zhang X, Hirose K, Kuroda I, Goi K, Honna H, Kagami K, Nakazawa S, Endo K, Kubota T, Yagita H, Koyama-Okazaki T, Sugita K: Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis. Exp Hematol; 2010 Oct;38(10):885-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
  • OBJECTIVE: Cytotoxic ligands are involved in tumor immunity and graft-vs.-leukemia effect after allogeneic stem cell transplantation for leukemia.
  • To clarify the susceptibility of T-cell acute lymphoblastic leukemia (T-ALL) to tumor immunity, sensitivity to recombinant human soluble Fas ligand (rhsFasL) and tumor necrosis factor-related apoptosis-inducing ligand (rhsTRAIL) was determined.
  • MATERIALS AND METHODS: Sensitivity to rhsFasL and rhsTRAIL and cell surface expression of their receptors were tested in T-ALL cell lines (n = 7) and patients' samples (n = 17) and compared with those in B-precursor ALL cell lines (n = 30).
  • Expression of components of the death-inducing signaling complex and the TRAIL receptor genes (DR4/DR5), and the methylation status and promoter activity of the DR4/DR5 gene were tested in T-ALL cell lines.
  • RESULTS: T-ALL cell lines showed higher level of Fas expression and higher sensitivity to rhsFasL than did B-precursor ALL cell lines.
  • Despite comparable expression of components of death-inducing signaling complex, cell lines and patients' samples of T-ALL showed TRAIL-resistance associated with low cell surface expression of DR4/DR5.
  • Gene expression of DR4/DR5 in T-ALL cell lines was significantly lower than that in B-precursor ALL cell lines, and the methylation status of the gene promoter in T-ALL cell lines was associated with the gene expression level at least for DR4.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Fas Ligand Protein / pharmacology. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Antigens, CD95 / metabolism. Cell Line, Tumor. Cells, Cultured. DNA Methylation / drug effects. Dose-Response Relationship, Drug. Drug Resistance. Flow Cytometry. Gene Expression / drug effects. Humans. Immunoblotting. Jurkat Cells. Luciferases / genetics. Luciferases / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Promoter Regions, Genetic / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20670671.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FAS protein, human; 0 / Fas Ligand Protein; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 1.13.12.- / Luciferases
  •  go-up   go-down


23. Kujawski L, Talpaz M: Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma; 2007 Dec;48(12):2310-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
  • Imatinib was the first treatment for chronic myeloid leukemia (CML) that specifically targeted the causative BCR-ABL oncoprotein, and represented a major therapeutic advance in this disease; however, some patients develop resistance or intolerance.
  • Resistance can be classified as BCR-ABL-dependent (e.g., mutation in the BCR-ABL gene) or BCR-ABL-independent (alternative pathways of disease progression, e.g., SRC-family tyrosine kinases).
  • Dasatinib is active across all phases of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia, and demonstrates activity in almost all imatinib-resistant mutations.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067005.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  • [Number-of-references] 104
  •  go-up   go-down


24. Sucić M, Batinić D, Zadro R, Mrsić S, Labar B: [Cytomorphology of acute mixed leukemia]. Acta Med Croatica; 2008 Oct;62(4):379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytomorphology of acute mixed leukemia].
  • Biphenotypic acute leukemias (AL) with blasts expressing both myeloid and lymphoid antigens are grouped with undifferentiated AL and bilineal AL in the group of AL of ambiguous lineage.
  • Not all AL with myeloid and lymphoid antigens (ALMy+Ly) are true biphenotypic AL.
  • According to EGIL scoring system, true biphenotypic ALMy+Ly are those with a sum of antigens 2 or more points for both myeloid and lymphoid lineage or for B and T lineage.
  • RESULTS AND DISCUSSION: In the group of 169 adult AL patients, 116 were cytomorphologically classified as acute myeloblastic leukemias (AML), 35 as acute lymphoblastic leukemias (ALL) and 18 as acute undifferentiated leukemias (ANLM).
  • In 6 (3.4%) of 169 AL patients, blasts expressed both myeloid and lymphoid antigens.
  • In 64 patients cytomorphologically classified into AML subgroup out of 102 AL patients, there were 15 (14.7%/102; 23.4%/64) AML with lymphoid antigens (AMLLy+).
  • In one ANLM,My+ out of 169 AL and also one ANLM,My+ out of 102 AL, blasts were cytomorphologically undifferentiated; in 3 ALLMy+ of 102 AL blasts expressed lymphoid morphology.
  • According to EGIL scoring system, among 15 AMLLy+ of 102 AL there were 4 true biphenotypic ALMy+Ly (1 M1, 2 M3, 1 M4), and in 4 ALMy+Ly with undifferentiated and lymphoid morphology there were 2 true biphenotypic AL (1 L2; 1 ANLM).
  • These observations are consistent with other studies and WHO determinations indicating that the majority of true biphenotypic leukemias are associated with immature monoblastic or myeloid cytomorphology or with lymphoid or undifferentiated characteristics, but may also express any AML cytomorphology type.
  • Thus, there is no direct correlation of leukemic cell cytomorphology and biphenotypic AL immunophenotype.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / pathology
  • [MeSH-minor] Acute Disease. Humans. Immunophenotyping. Leukemia, Myeloid, Acute / classification. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205415.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


25. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL: JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A; 2009 Jun 9;106(23):9414-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAK mutations in high-risk childhood acute lymphoblastic leukemia.
  • Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations.
  • We recently identified a poor prognostic subgroup of pediatric BCR-ABL1-negative ALL patients characterized by deletion of IKZF1 (encoding the lymphoid transcription factor IKAROS) and a gene expression signature similar to BCR-ABL1-positive ALL, raising the possibility of activated tyrosine kinase signaling within this leukemia subtype.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Sep 27;20(43):6188-95 [11593427.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47954-63 [12351625.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Nature. 1996 Jul 25;382(6589):325-31 [8684460.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Nature. 1998 Sep 17;395(6699):237-43 [9751050.001]
  • [Cites] Nature. 1998 Sep 17;395(6699):244-50 [9751051.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):41893-9 [16239216.001]
  • [Cites] Blood. 2006 Jan 1;107(1):176-83 [16174768.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6468-72 [16818614.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):673-83 [17721432.001]
  • [Cites] Mol Cell Biol. 2008 Mar;28(5):1792-801 [18160720.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] J Exp Med. 2008 Apr 14;205(4):751-8 [18362173.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2190-8 [18779404.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):335-43 [18835035.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Semin Cell Dev Biol. 2008 Aug;19(4):385-93 [18682296.001]
  • [Cites] Blood. 2009 Jan 15;113(3):646-8 [18927438.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • (PMID = 19470474.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA118100; United States / NCI NIH HHS / CA / U10 CA98413; United States / NCI NIH HHS / CA / L40 CA142226; United States / NCI NIH HHS / CA / U01 CA114762; United States / NCI NIH HHS / CA / CA114762; United States / NCI NIH HHS / CA / U10 CA098413; United States / PHS HHS / / N01-C0-12400; United States / NCI NIH HHS / CA / CA098543; United States / Howard Hughes Medical Institute / / ; United States / NICHD NIH HHS / HD / T32 HD044331; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / T32 CA128583; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IKZF1 protein, human; 148971-36-2 / Ikaros Transcription Factor; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.10.2 / Janus Kinase 3; EC 2.7.10.2 / Janus Kinases
  • [Other-IDs] NLM/ PMC2695045
  •  go-up   go-down


26. Timuragaoglu A, Dizlek S, Uysalgil N, Tosun O, Yamac K: Methylenetetrahydrofolate reductase C677T polymorphism in adult patients with lymphoproliferative disorders and its effect on chemotherapy. Ann Hematol; 2006 Dec;85(12):863-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because folate is the cornerstone in DNA synthesis, we analysed herein if the polymorphisms in MTHFR gene can alter the susceptibility of lymphoproliferative disease risk and if it has an effect on chemotherapy response.
  • One hundred fifty-six patients with lymphoid malignancies and 82 healthy controls were included into the study.
  • Neither gene frequencies nor allel frequencies were found to increase lymphoproliferative disease risk significantly in both overall group and subgroups.
  • Although it was not statistically significant, we found a 2.7-fold increased risk in acute lymphocytic leukaemia (ALL)/Burkitt lymphoma patients with TT genotype [odds ratio (OR), 2.7; 95% confidence interval (CI), 0.88-8.2] than CC genotype but a 1.7-fold decreased risk with TT genotype in diffuse large B-cell lymphoma (DLBCL; OR, 0.58; 95% CI, 0.17-1.88) and a 1.8-fold decreased risk in Hodgkin's lymphoma with TT genotype (OR, 0.55; 95% CI, 0.10-2.87) than CC genotype.
  • The chemotherapy response was analysed in DLBCL, Hodgkin's lymphoma and ALL/Burkitt's lymphoma because these patients received standard chemotherapy protocols.
  • As a conclusion, MTHFR C677T polymorphism does not increase the risk of lymphoproliferative disease, and it does not have an effect on chemotherapy response significantly; however, the patients with TT genotype have a slightly increased risk for ALL, and they also respond worse than CC genotype.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Female. Genetic Predisposition to Disease. Genotype. Hodgkin Disease / drug therapy. Hodgkin Disease / genetics. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / genetics. Male. Middle Aged. Risk. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Hematol. 2007 May;86(5):389 [17211521.001]
  • (PMID = 16944145.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


27. Leclerc GJ, Sanderson C, Hunger S, Devidas M, Barredo JC: Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia. Leuk Res; 2010 Dec;34(12):1601-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.
  • Acute Lymphoblastic Leukemia (ALL) non-random fusions influence clinical outcome and alter the accumulation of MTX-PGs in vivo.
  • Using an FPGS-luciferase reporter gene assay, we determined that E2A-PBX1 and TEL-AML1 expression decreased FPGS transcription.
  • ChIP assays uncovered HDAC1, AML1, mSin3A, E2F, and Rb interactions with the FPGS promoter region.
  • We demonstrate that FPGS expression is epigenetically regulated through binding of selected ALL fusions to a multiprotein complex, which also controls the cell cycle dependence of FPGS expression.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):942-51 [11309345.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1081-8 [11455977.001]
  • [Cites] J Mol Biol. 2001 May 25;309(1):99-120 [11491305.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S31-4 [11587363.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):437-46 [11821956.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jan;3(1):11-20 [11823794.001]
  • [Cites] Lancet Oncol. 2001 Oct;2(10):597-607 [11902549.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 21;1602(2):131-50 [12020800.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Clin Chem. 2003 Feb;49(2):230-8 [12560344.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):48-54 [12573435.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):688-95 [12972803.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6012-9 [14676127.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4275-83 [15156184.001]
  • [Cites] J Leukoc Biol. 2004 Sep;76(3):623-33 [15197237.001]
  • [Cites] Cell. 1974 Jul;2(3):183-8 [4472030.001]
  • [Cites] Leuk Res. 1989;13(8):683-8 [2796376.001]
  • [Cites] Blood. 1990 Jul 1;76(1):44-9 [1694703.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2557-61 [11001911.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):871-7 [10544023.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1316-23 [1381244.001]
  • [Cites] Leukemia. 2010 Mar;24(3):552-62 [20072153.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2020-3 [18544682.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):410-26 [18297517.001]
  • [Cites] Mol Cancer. 2007;6:46 [17623090.001]
  • [Cites] Leuk Res. 2007 Mar;31(3):293-9 [16884772.001]
  • [Cites] Mol Pharmacol. 1992 Oct;42(4):687-94 [1435744.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] J Biol Chem. 1995 Apr 21;270(16):9579-84 [7721888.001]
  • [Cites] Leuk Res. 1996 May;20(5):441-3 [8683984.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):9-15 [8907263.001]
  • [Cites] J Cell Biochem. 1997 Oct 1;67(1):24-31 [9328836.001]
  • [Cites] Leuk Lymphoma. 1998 Nov;31(5-6):507-19 [9922041.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):296-308 [10460585.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6566-74 [10490596.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R77-84 [15809276.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;Suppl:S16-7 [15962527.001]
  • [Cites] Clin Ther. 2005 Sep;27(9):1343-82 [16291410.001]
  • [Cites] Haematologica. 2005 Dec;90(12):1697-9 [16330447.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] BMC Cancer. 2006;6:132 [16707018.001]
  • [CommentIn] Leuk Res. 2010 Dec;34(12):1558-9 [20594594.001]
  • (PMID = 20538338.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / CA098152-06; United States / NCI NIH HHS / CA / R01 CA098152-06; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA098152; United States / NCI NIH HHS / CA / CA98413
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / Multiprotein Complexes; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RUNX1 protein, human; 0 / Retinoblastoma Protein; 0 / TCF3 protein, human; 0 / TEL-AML1 fusion protein; 0 / pbx1 protein, human; EC 3.5.1.98 / HDAC1 protein, human; EC 3.5.1.98 / Histone Deacetylase 1; EC 6.3.2.- / Peptide Synthases; EC 6.3.2.17 / folylpolyglutamate synthetase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS212801; NLM/ PMC2946984
  •  go-up   go-down


28. Naithani R, Dolai TK, Kumar R: Bilateral vocal cord paralysis following treatment with vincristine. Indian Pediatr; 2009 Jan;46(1):68-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a child with acute lymphoblastic leukemia who developed vincristine-induced bilateral vocal cord paralysis.
  • [MeSH-minor] Adolescent. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - paralysis.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179723.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


29. Terme JM, Lhermitte L, Asnafi V, Jalinot P: TGF-beta induces degradation of TAL1/SCL by the ubiquitin-proteasome pathway through AKT-mediated phosphorylation. Blood; 2009 Jun 25;113(26):6695-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T-cell acute lymphoblastic leukemia 1 (TAL1), also known as stem cell leukemia (SCL), plays important roles in differentiation of hematopoietic and endothelial cells and is deregulated in a high percentage of T-cell acute lymphoblastic leukemia (T-ALL).

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406989.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Leupeptins; 0 / Neoplasm Proteins; 0 / Proteasome Inhibitors; 0 / Proto-Oncogene Proteins; 0 / TCF Transcription Factors; 0 / TCF7L1 protein, human; 0 / Transcription Factor 7-Like 1 Protein; 0 / Transforming Growth Factor beta1; 0 / Ubiquitin; 1114-81-4 / Phosphothreonine; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 135471-20-4 / TAL1 protein, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 6.3.2.19 / STUB1 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases; XVA4O219QW / wortmannin
  •  go-up   go-down


30. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, Ariola C, Fodale V, Clappier E, Paoloni F, Martinelli S, Fragale A, Sanchez M, Tavolaro S, Messina M, Cazzaniga G, Camera A, Pizzolo G, Tornesello A, Vignetti M, Battistini A, Cavé H, Gelb BD, Renauld JC, Biondi A, Constantinescu SN, Foà R, Tartaglia M: Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med; 2008 Apr 14;205(4):751-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.
  • The Janus kinase 1 (JAK1) gene encodes a cytoplasmic tyrosine kinase that noncovalently associates with a variety of cytokine receptors and plays a nonredundant role in lymphoid cell precursor proliferation, survival, and differentiation.
  • We report that somatic mutations in JAK1 occur in individuals with acute lymphoblastic leukemia (ALL).
  • JAK1 mutations were more prevalent among adult subjects with the T cell precursor ALL, where they accounted for 18% of cases, and were associated with advanced age at diagnosis, poor response to therapy, and overall prognosis.
  • Three mutations that were studied promoted JAK1 gain of function and conferred interleukin (IL)-3-independent growth in Ba/F3 cells and/or IL-9-independent resistance to dexamethasone-induced apoptosis in T cell lymphoma BW5147 cells.
  • Our findings implicate dysregulated JAK1 function in ALL, particularly of T cell origin, and point to this kinase as a target for the development of novel antileukemic drugs.
  • [MeSH-major] Janus Kinase 1 / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Alleles. Animals. Base Sequence. Cell Line, Tumor. DNA Mutational Analysis. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Humans. Mice. Models, Molecular. Molecular Sequence Data. Mutant Proteins / metabolism


31. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer; 2005 Apr 15;103(8):1659-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
  • BACKGROUND: The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML).
  • Early studies demonstrated high rates of hematologic and cytogenetic responses in all phases of the disease after limited observation periods.
  • METHODS: The authors evaluated long-term outcome, rates of response, and resistance in 300 patients with BCR-ABL-positive leukemias (CML in chronic phase after failure to respond to interferon-alpha [CP], n = 139; accelerated phase [AP], n = 80; myeloid blast crisis [BC], n = 76; lymphoid BC and Philadelphia chromosome-positive acute lymphoblastic leukemia, n = 5) who entered clinical trials with imatinib in a single center after an observation time of 4.5 years.
  • In myeloid BC, the median survival period after the start of imatinib and after diagnosis of BC was 6 and 9 months, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Blast Crisis. Cytogenetic Analysis. Female. Humans. Imatinib Mesylate. Interferon-alpha / adverse effects. Male. Middle Aged. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15747376.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Interferon-alpha; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


32. Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg SM, Wayne AS, Pastan I: Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol; 2010 Aug;150(3):352-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia (ALL) remains the most frequent cause of cancer-related mortality in paediatrics and outcome is poor for patients who have high-risk ALL or relapse.
  • Using a bone marrow mesenchymal cell culture assay to support ALL cell viability, we investigated the in vitro cytotoxicity of HA22 against ALL blasts from newly diagnosed (n = 13) and relapsed patients (n = 22).
  • There was no significant difference in HA22 sensitivity between diagnosis and relapse samples but peripheral blood ALL blasts were more sensitive to HA22 than those from bone marrow (P = 0.008).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bacterial Toxins / pharmacology. Exotoxins / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Sialic Acid Binding Ig-like Lectin 2 / immunology
  • [MeSH-minor] Adolescent. Antineoplastic Agents, Hormonal / pharmacology. Cell Death / drug effects. Child. Child, Preschool. Dexamethasone / pharmacology. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Female. Humans. Infant. Lethal Dose 50. Male. Tumor Cells, Cultured. Young Adult

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528877.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Bacterial Toxins; 0 / Exotoxins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / immunotoxin HA22; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


33. Rozanov S, Keren O, Karni A: The specificity of memory for a highly trained finger movement sequence: Change the ending, change all. Brain Res; 2010 May 17;1331:80-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The specificity of memory for a highly trained finger movement sequence: Change the ending, change all.
  • How are highly trained movement sequences represented in long-term memory?
  • Here we show that the gains attained in the performance of a well-trained sequence of finger movements can be expressed only when the order of the movements is exactly as practiced.
  • Ten young adults were trained to perform a given 5-element sequence of finger-to-thumb opposition movements with their left hand.
  • Movements were analyzed using video based tracking.
  • Three weeks of training resulted, along with improved accuracy, in robustly shortened movement times as well as shorter finger-to-thumb touch times.
  • However, there was little transfer of these gains in speed to the execution of the same component movements arranged in a new order.
  • Moreover, even when the only change was the omission of the one before final movement of the trained sequence (Omit sequence), the initial movements of the sequence were significantly slowed down, although these movements were identical to the initial movements of the trained sequence.
  • Our results support the notion that a well-trained sequence of finger movements can be represented, in the adult motor system, as a singular, co-articulated, unit of movement, in which even the initial component movements are contingent on the subsequent, anticipated, ones.
  • Because of co-articulation related anticipatory effects, gains in fluency and accuracy acquired in training on a specific movement sequence cannot be expressed in full in the execution of the trained component movements or of a full segment of the trained sequence, if followed by a different ending segment.
  • [MeSH-major] Memory / physiology. Motor Skills / physiology
  • [MeSH-minor] Adult. Female. Fingers / innervation. Fingers / physiology. Humans. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier B.V.
  • (PMID = 20298683.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Daniel-Cravioto A, Gonzalez-Bonilla CR, Mejia-Arangure JM, Perez-Saldivar ML, Fajardo-Gutierrez A, Jimenez-Hernandez E, Hernandez-Serrano M, Bekker-Mendez VC: Genetic rearrangement MLL/AF4 is most frequent in children with acute lymphoblastic leukemias in Mexico City. Leuk Lymphoma; 2009 Aug;50(8):1352-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic rearrangement MLL/AF4 is most frequent in children with acute lymphoblastic leukemias in Mexico City.
  • One of the highest incidences of acute lymphoblastic leukemia (ALL) in the world has been reported in Mexico City.
  • [MeSH-major] Biomarkers, Tumor / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Base Sequence. Birth Weight. Child. Child, Preschool. Core Binding Factor Alpha 2 Subunit / genetics. Environmental Exposure. Female. Fusion Proteins, bcr-abl / genetics. Gene Frequency. Genetic Predisposition to Disease. Humans. Infant. Male. Mexico / epidemiology. Molecular Sequence Data. Pregnancy. Prenatal Exposure Delayed Effects. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic. Urban Population

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579075.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Core Binding Factor Alpha 2 Subunit; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


35. Organista-Nava J, Gómez-Gómez Y, Saavedra-Herrera MV, Rivera-Ramírez AB, Terán-Porcayo MA, Alarcón-Romero Ldel C, Illades-Aguiar B, Leyva-Vázquez MA: Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leuk Res; 2010 Jun;34(6):728-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico.
  • This study evaluated the association of -401C/T and +452C/T polymorphisms of gamma-glutamyl hydrolase and the risk of relapse to acute lymphoblastic leukemia.
  • Genotyping was performed in 70 children with acute lymphoblastic leukemia and 140 healthy children.
  • An association between the -401C/T polymorphism and the risk of relapse was found (p=0.028), patients with the -401T/T genotype have 10.83 (95% CI 1.30-90.14) more chance of a relapse of leukemia.
  • Therefore, our investigation suggests that the -401C/T polymorphism in the gamma-glutamyl hydrolase may be a factor involved in the generation of relapse to disease in patients with ALL.
  • [MeSH-major] Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. gamma-Glutamyl Hydrolase / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20197200.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 3.4.19.9 / gamma-Glutamyl Hydrolase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


36. Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G: Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia; 2008 Dec;22(12):2193-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
  • The aim of the study was to analyze the impact of minimal residual disease (MRD) after reinduction therapy on the outcome of children with relapsed 'high-risk' acute lymphoblastic leukemia (ALL).
  • MRD quantitation early and efficiently differentiates patients who benefit from conventional treatment, including allogeneic hematopoietic stem cell transplantation, from those needing innovative, experimental therapies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm, Residual / drug therapy. Neoplasm, Residual / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Asparaginase / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant. Male. Methotrexate / therapeutic use. Multivariate Analysis. Predictive Value of Tests. Prednisone / therapeutic use. Prognosis. Prospective Studies. Recurrence. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754029.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


37. Valera ET, Brassesco MS, Germeshausen M, Silveira Vda S, Queiroz RG, Roxo P, Scrideli CA, de Menezes UP, Ferriani V, Tone LG: Acute lymphoblastic leukemia following severe congenital neutropenia or de novo ALL? Leuk Res; 2009 Sep;33(9):e139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia following severe congenital neutropenia or de novo ALL?
  • Acute lymphoblastic leukemia (ALL) presenting with neutropenia alone is very rare.
  • We identified a rare loss of 5'-MLL present at the diagnosis of SCN and ALL by FISH analysis using two different MLL (11q23) probes.
  • The early presence of 5'-MLL loss in bone marrow samples may favor the diagnosis of de novo ALL.
  • [MeSH-major] Neutropenia / congenital. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398129.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


38. Koca E, Goker H, Guven GS, Cetiner D, Haznedaroglu IC, Buyukasik Y, Uner A, Ozcebe OI: Unusual extramedullary recurrences and breast relapse despite hepatic GVHD after allografting in Ph+-ALL. Hematology; 2006 Apr;11(2):105-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our report describes a case of an extramedullary recurrence and breast relapse after second-allografting in a female patient with Ph+-acute lymphoblastic leukemia (ALL), occurring when there was active hepatic GHVD.
  • This case illustrates the complex relationship between graft-versus-host disease (GVHD) and graft-versus-leukemia since she had no evidence of leukemia in her marrow demonstrating 100% full-donor chimerism while she had ALL relapse in her breast.
  • [MeSH-major] Breast / pathology. Graft vs Host Disease. Leukemic Infiltration / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Female. Hematopoietic Stem Cell Transplantation. Humans. Liver / pathology. Middle Aged. Philadelphia Chromosome. Preleukemia / therapy. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753850.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Visser O, van Wijnen JH, van Leeuwen FE: Incidence of cancer in the area around Amsterdam Airport Schiphol in 1988-2003: a population-based ecological study. BMC Public Health; 2005;5:127
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found a statistically significantly increased incidence of hematological malignancies (SIR 1.12, 95% confidence interval [CI]: 1.05, 1.19), mainly due to high rates for non-Hodgkin lymphoma (SIR 1.22, 95% CI: 1.12, 1.33) and acute lymphoblastic leukemia (SIR 1.34, 95% CI: 0.95, 1.83).

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1990;18(3):303-5 [2220835.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):647-52 [15252832.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):411-7 [8517656.001]
  • [Cites] Soc Sci Med. 1993 Sep;37(6):771-7 [8211293.001]
  • [Cites] Eur J Cancer. 1994;30A(4):469-73 [8018404.001]
  • [Cites] Occup Environ Med. 1995 Jun;52(6):374-9 [7627313.001]
  • [Cites] Eur J Cancer. 1995 Oct;31A(11):1822-9 [8541107.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:219-24 [8741787.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):729-36 [8921449.001]
  • [Cites] Ned Tijdschr Geneeskd. 1997 Mar 8;141(10):468-73 [9173287.001]
  • [Cites] Scand J Work Environ Health. 1998 Aug;24(4):255-61 [9754856.001]
  • [Cites] Ned Tijdschr Geneeskd. 1983 Aug 20;127(34):1516-25 [6633686.001]
  • [Cites] Br Med J. 1976 Dec 25;2(6051):1525-36 [1009386.001]
  • [Cites] Environ Health Perspect. 1978 Feb;22:23-31 [648488.001]
  • [Cites] Scand J Work Environ Health. 1999 Oct;25(5):436-41 [10569464.001]
  • [Cites] Rev Environ Health. 2000 Jan-Jun;15(1-2):83-96 [10939086.001]
  • [Cites] Stat Med. 2000 Sep 15-30;19(17-18):2569-78 [10960872.001]
  • [Cites] Int J Epidemiol. 2001 Aug;30(4):839-45 [11511614.001]
  • [Cites] Occup Environ Med. 2001 Dec;58(12):769-73 [11706142.001]
  • [Cites] Environ Res. 2002 Mar;88(3):182-7 [12051796.001]
  • [Cites] Cancer Causes Control. 2002 Aug;13(6):563-71 [12195646.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):295-300 [15093276.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):803-10 [2010224.001]
  • (PMID = 16332253.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Vehicle Emissions
  • [Other-IDs] NLM/ PMC1325225
  •  go-up   go-down


40. Eiser C, Eiser JR, Stride CB: Quality of life in children newly diagnosed with cancer and their mothers. Health Qual Life Outcomes; 2005;3:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: With current treatments, approximately 75% of children diagnosed with cancer can expect to achieve disease-free survival.
  • Although previous work has shown increased anxiety and depression among parents after diagnosis, the recent development of standardised measures of QOL enables us to look more directly at the impact of diagnosis on mothers' and children's QOL.
  • The aims of this study are to i) describe QOL for children and their mothers after diagnosis by comparing their scores with population norms, ii) explore the relationship between mothers' worries about the illness and their QOL, and iii) determine the relationship between mothers ratings of their own QOL and their child.
  • Diagnoses were acute lymphoblastic leukaemia (ALL, n = 57), brain tumours (n = 11), bone tumours (n = 17) and 2 rare cancers.
  • CONCLUSION: Both children and their mothers experience significantly compromised QOL in the months following diagnosis.
  • Efforts must continue to be made to improve QOL of children especially in the period immediately following diagnosis.
  • [MeSH-minor] Adolescent. Anxiety. Bone Neoplasms / psychology. Bone Neoplasms / therapy. Brain Neoplasms / psychology. Brain Neoplasms / therapy. Child. Child, Preschool. Female. Great Britain. Health Knowledge, Attitudes, Practice. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Proxy. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Apr;82(7):1339-43 [10755411.001]
  • [Cites] Acta Paediatr. 2000 Apr;89(4):386-92 [10830445.001]
  • [Cites] Health Technol Assess. 2001;5(4):1-157 [11262421.001]
  • [Cites] J Child Psychol Psychiatry. 2001 Jul;42(5):661-7 [11464970.001]
  • [Cites] J Pediatr Psychol. 2004 Apr-May;29(3):231-40 [15131140.001]
  • [Cites] BMJ. 1993 May 29;306(6890):1437-40 [8518639.001]
  • [Cites] Health Qual Life Outcomes. 2005;3:22 [15804349.001]
  • [Cites] BMJ. 1994 Dec 17;309(6969):1612-6 [7819936.001]
  • [Cites] Psychooncology. 1997 Jun;6(2):115-28 [9205969.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1998 Aug;37(8):815-22 [9695443.001]
  • [Cites] J Pediatr Psychol. 1998 Aug;23(4):257-66 [9718899.001]
  • [Cites] Med Care. 1999 Feb;37(2):126-39 [10024117.001]
  • [Cites] J Behav Med. 1999 Aug;22(4):397-406 [10495970.001]
  • [Cites] J Pediatr Psychol. 1993 Jun;18(3):365-76 [8340845.001]
  • (PMID = 15860126.001).
  • [ISSN] 1477-7525
  • [Journal-full-title] Health and quality of life outcomes
  • [ISO-abbreviation] Health Qual Life Outcomes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1097748
  •  go-up   go-down


41. Figliolia SL, Oliveira DT, Pereira MC, Lauris JR, Maurício AR, Oliveira DT, Mello de Andrea ML: Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients. Oral Dis; 2008 Nov;14(8):761-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients.
  • The purpose of this retrospective study was to estimate the prevalence and risk factors of oral mucositis in 169 acute lymphoblastic leukaemia (ALL) patients treated according to different chemotherapeutic trials at the Darcy Vargas Children's Hospital from 1994 to 2005.
  • The association of oral mucositis with age, gender, leucocyte counts at diagnosis and treatment was assessed by the chi-squared test and multivariate regression analysis.
  • Patient age (P = 0.33), gender (P = 0.08) and leucocyte counts at diagnosis (P = 0.34) showed no correlation with the occurrence of oral mucositis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Stomatitis / epidemiology

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18761642.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol
  •  go-up   go-down


42. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H: Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs; 2007 Jul;10(7):468-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
  • Chronic myelocytic leukemia (CML) is caused by the constitutively active tyrosine kinase Bcr-Abl.
  • In a phase II clinical trial in CML, major cytogenetic response rates were 52 and 33% for chronic- and accelerated-phase disease, respectively.
  • Nilotinib has been filed for approval in the US and EU for use in Philadelphia-positive leukemias in patients who are resistant or intolerant to imatinib.
  • Nilotinib is undergoing clinical trials in patients with newly diagnosed CML, acute lymphoblastic leukemia and gastrointestinal stromal tumors, among other indications.
  • [MeSH-major] Antineoplastic Agents. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Protein Kinase Inhibitors. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642017.001).
  • [ISSN] 1369-7056
  • [Journal-full-title] IDrugs : the investigational drugs journal
  • [ISO-abbreviation] IDrugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


43. Zanrosso CW, Hatagima A, Emerenciano M, Ramos F, Figueiredo A, Félix TM, Segal SL, Giugliani R, Muniz MT, Pombo-de-Oliveira MS: The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population. Leuk Res; 2006 Apr;30(4):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population.
  • In order to investigate the influence of two polymorphisms in the MTHFR gene, 677C>T and 1298A>C, on the risk of acute lymphoblastic leukemia (ALL) we performed a case-control study in children from different Brazilians' regions.
  • Genotyping of 176 ALL and 199 unselected healthy subjects was performed using PCR-RFLP assay.
  • Our investigation provides interesting data concerning the opposite effect of A1298C polymorphisms, particularly in the light of relatively scarce data regarding the MTHFR role in leukemia susceptibility in different populations.
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Leuk Res. 2009. doi: 10.1016/j.leukres.2009.01.019. Guigliani, Roberto [corrected to Giugliani, Roberto]
  • [ErratumIn] Leuk Res. 2009 Jul;33(7):1009
  • (PMID = 16182363.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


44. Liu DH, Liu KY, Xu LP, Han W, Chen H, Chen YH, Zhang XH, Huang XJ: [Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi; 2008 Feb;29(2):78-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation].
  • OBJECTIVE: To observe the efficacy and safety of donor lymphocyte infusion (DLI) for treatment of leukemia relapse after HLA-mismatched hematopoietic stem cell transplantation (HSCT).
  • METHODS: Patients received DLI were studied for the occurrence of graft-versus-host disease (GVHD) , remission of leukemia and long-term survival after granulocyte colony-stimulating factor (G-CSF).
  • RESULTS: Acute grade III - IV GVHD was observed in 8 of 24 patients relapsed after HSCT and GVHD prophylaxis reduced the incidence (P = 0.013).
  • Nine of them survived leukemia-free for a median of 1310 (961 - 1914) days after HSCT.
  • The 1-year and 2-year probability of leukemia-free survival was 60% and 40%, respectively.
  • All three patients with Ph-positive acute lymphoblastic leukemia died of relapse.
  • CONCLUSION: The G-CSF-primed DLI with GVHD prophylaxis(some combined with chemotherapy) is a potentially effective therapeutic option for patients with relapsed leukemia after HLA-mismatched HSCT.
  • [MeSH-major] Leukemia / therapy. Lymphocyte Transfusion
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Graft vs Host Disease / prevention & control. Granulocyte Colony-Stimulating Factor / therapeutic use. HLA Antigens. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681305.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA Antigens; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


45. Attarbaschi A, Mann G, König M, Steiner M, Strehl S, Schreiberhuber A, Schneider B, Meyer C, Marschalek R, Borkhardt A, Pickl WF, Lion T, Gadner H, Haas OA, Dworzak MN: Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res; 2006 May 15;12(10):2988-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity.
  • PURPOSE: Mixed lineage leukemia (MLL) abnormalities occur in approximately 50% of childhood pro-B acute lymphoblastic leukemia (ALL).
  • RESULTS: We found that 15 of 29 pro-B ALL, 7 of 11 CD10- pre-B ALL, and 1 of 2 French-American-British classification L1 mature B-cell leukemia cases had a MLL rearrangement.
  • MLL-rearranged pro-B and CD10- pre-B ALL cases had similar clinical and immunophenotypic (coexpression of CDw65 and CD15) features at initial diagnosis.
  • CONCLUSIONS: The striking similarities between the two CD10- ALL subsets imply that CD10- pre-B ALL variants may represent pro-B ALL cases that maintained the propensity to rearrange and express their immunoglobulin heavy chain rather than actual pre-B ALL forms transformed at this later stage of B-cell differentiation.
  • [MeSH-major] Chromosome Aberrations. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707593.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


46. Bender A: How similar are those molecules after all? Use two descriptors and you will have three different answers. Expert Opin Drug Discov; 2010 Dec;5(12):1141-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How similar are those molecules after all? Use two descriptors and you will have three different answers.
  • IMPORTANCE OF THE FIELD: Molecular similarity searching (ligand-based virtual screening) is one of the routine computational techniques used in drug discovery and pharmacological research.
  • However, while a large number of descriptors exist, there are no general guidelines whatsoever which descriptors work better and which descriptors should be used in the different cases.
  • AREAS COVERED IN THIS REVIEW: This review provides a brief overview of current molecular descriptors and databases used for their evaluation, followed by a critical discussion of their differences.
  • WHAT THE READER WILL GAIN: After reading this review, the reader will be aware of how very differently molecular descriptors assess similarities of molecules, and the performance that can be realistically expected from them.
  • TAKE HOME MESSAGE: Molecular descriptors come in a variety of forms, and they show vast differences in assessing the similarity between molecules.
  • Virtual screening performance of many descriptors is often lower than expected, compared to 'dumb' descriptors while some simple methods such as circular fingerprints offer surprisingly good performance in many cases.
  • The choice of the right benchmark library is crucial, many of which are summarized in this review.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22822717.001).
  • [ISSN] 1746-045X
  • [Journal-full-title] Expert opinion on drug discovery
  • [ISO-abbreviation] Expert Opin Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Grieco A, Miele L, Pompili M, Biolato M, Vecchio FM, Grattagliano I, Gasbarrini G: Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all. J Hepatol; 2009 Jun;50(6):1273-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all.
  • The episode was regarded as an adverse drug reaction after exclusion of other possible causes of acute liver disease and the prompt normalization of liver function tests after Equisterol had been discontinued.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Hepatol. 2010 Mar;52(3):466
  • (PMID = 19398239.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Biological Products; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Hypolipidemic Agents; 0 / Plant Extracts; 0 / Plant Gums; 0 / guggulu extract; 0 / red yeast rice; 9LHU78OQFD / Lovastatin; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


48. Luciani M, Rana I, Pansini V, Caniglia M, Coletti V, Maraschini A, Lombardi A, De Rossi G: Infant leukaemia: clinical, biological and therapeutic advances. Acta Paediatr Suppl; 2006 Jul;95(452):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant leukaemia: clinical, biological and therapeutic advances.
  • Infant acute lymphoid leukaemia (IALL) represents a distinct subset with an extremely poor response to therapy, despite major progress in the treatment of childhood leukaemia.
  • Therefore, an international protocol (Interfant 99) was recently started, using a more aggressive approach, which included lymphoid- and myeloid-specific drugs, and indications for stem-cell transplantation.
  • We reviewed the clinical characteristics of the disease, the results of several recent international clinical trials, and our experience with 16 infants with acute lymphoid leukaemia diagnosed and treated at our institution.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Infant. Italy / epidemiology. Male. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801167.001).
  • [ISSN] 0803-5326
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992). Supplement
  • [ISO-abbreviation] Acta Paediatr Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


49. Jaime-Pérez JC, Gómez-Almaguer D, Sandoval-González A, Chapa-Rodríguez A, Gonzàlez-Llano O: Random serum methotrexate determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia. Leuk Lymphoma; 2009 Nov;50(11):1843-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Random serum methotrexate determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia.
  • The cure rate for acute lymphoblastic leukemia (ALL) may exceed 85%.
  • [MeSH-major] Methotrexate / therapeutic use. Patient Compliance / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


50. Rajić V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I, Jazbec J: Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma; 2009 Oct;50(10):1693-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood.
  • The hypothesis was tested in a cohort of 76 long-term survivals of acute lymphoblastic leukemia in childhood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiomyopathies / genetics. Genetic Association Studies. Heart / drug effects. Myocardium / pathology. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Survivors


51. Gümüş H, Per H, Kumandaş S, Yikilmaz A: Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature. Neurol Sci; 2010 Apr;31(2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reversible posterior leukoencephalopathy syndrome (RPLS) is recently described disorder with typical radiological findings in the posterior regions of the cerebral hemisphere and cerebellum.
  • We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.
  • Early recognition of RPLS as complication during different diseases and therapy in childhood may facilitate precise diagnosis and appropriate treatment.
  • [MeSH-major] Posterior Leukoencephalopathy Syndrome / diagnosis
  • [MeSH-minor] Adolescent. Brain / pathology. Child. Diagnosis, Differential. Early Diagnosis. Female. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Aug;21(7):1199-206 [10954269.001]
  • [Cites] J Neurol. 2002 Jun;249(6):780-1 [12173578.001]
  • [Cites] Neurology. 1999 Apr 12;52(6):1285-8 [10214762.001]
  • [Cites] Epilepsia. 1998 Mar;39(3):295-9 [9578048.001]
  • [Cites] Stroke. 1997 May;28(5):1082-5 [9158653.001]
  • [Cites] Pediatr Radiol. 2005 Jul;35(7):722-7 [15756541.001]
  • [Cites] Pediatr Nephrol. 2001 Jul;16(7):601-3 [11465812.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):591 [9541327.001]
  • [Cites] Radiology. 2001 Jun;219(3):756-65 [11376265.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jan;271(1):79-85 [15480723.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):1038-48 [12063238.001]
  • [Cites] Pediatr Neurol. 1999 Mar;20(3):241-3 [10207937.001]
  • [Cites] Pediatr Neurol. 2006 Mar;34(3):245-7 [16504799.001]
  • [Cites] Eur J Neurol. 2006 Mar;13(3):309-10 [16618354.001]
  • [Cites] Ann Intern Med. 1995 Oct 15;123(8):598-600 [7677301.001]
  • [Cites] Intern Med J. 2005 Feb;35(2):83-90 [15705136.001]
  • [Cites] Nephrol Dial Transplant. 1989;4(12):1065-9 [2517327.001]
  • [Cites] AJR Am J Roentgenol. 1992 Aug;159(2):379-83 [1632361.001]
  • [Cites] Pediatr Infect Dis J. 2006 Jan;25(1):85-7 [16395114.001]
  • [Cites] Curr Opin Pediatr. 1999 Dec;11(6):512-8 [10590909.001]
  • [Cites] Radiology. 1991 Aug;180(2):475-8 [2068315.001]
  • [Cites] Eur J Pediatr. 2004 Dec;163(12):728-30 [15322868.001]
  • [Cites] Pediatr Neurol. 2001 May;24(5):361-4 [11516610.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):198-203 [16123992.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Jun-Jul;16(6):1344-6 [7677037.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):447-55 [18079186.001]
  • [Cites] Radiology. 2000 Nov;217(2):371-6 [11058630.001]
  • [Cites] Pediatr Nephrol. 2003 Nov;18(11):1161-6 [14505162.001]
  • [Cites] Pediatr Nephrol. 1993 Apr;7(2):194-5 [8476718.001]
  • [Cites] Neurology. 2001 Feb 13;56(3):388-91 [11171907.001]
  • [Cites] Neurology. 1998 Nov;51(5):1369-76 [9818862.001]
  • [Cites] J Comput Assist Tomogr. 2007 Jan-Feb;31(1):148-56 [17259848.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):494-500 [8559202.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Aug;99(3):222-6 [9350407.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jan;18(1):101-6 [9010526.001]
  • [Cites] Postgrad Med J. 2001 Jan;77(903):24-8 [11123390.001]
  • [Cites] Blood. 2003 Jan 15;101(2):415-9 [12393443.001]
  • [Cites] Neurology. 1997 Oct;49(4):1174-5 [9339716.001]
  • [Cites] BMJ. 1989 Nov 18;299(6710):1258-9 [2513901.001]
  • (PMID = 19809787.001).
  • [ISSN] 1590-3478
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 42
  •  go-up   go-down


52. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A, Tallman MS: Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood; 2007 Dec 15;110(13):4172-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival.
  • In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission but also for relapse-free survival (RFS).
  • However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Blast Crisis / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction / methods. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2008 Feb 1;111(3):1746-7 [18223180.001]
  • (PMID = 17909077.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


53. Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, Marguerite G, Mazingue F, Renard M, Lutz P, Rialland X, Mechinaud F, Cavé H, Baila L, Bertrand Y, Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC): Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer; 2008 Apr;44(6):840-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial.
  • From June 1989 through to November 1998, 121 children with newly diagnosed T-cell lymphoblastic lymphoma (T-LBL) were included in the EORTC 58881 trial conducted by the Children's Leukaemia Group.
  • Cranial irradiation, prophylactic cranial and local, was omitted, even for patients with central nervous involvement at diagnosis.
  • An intensive acute lymphoblastic leukaemia type chemotherapy regimen without irradiation leads to a high cure and survival rate in childhood T-LBL without an increased CNS recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342502.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-18; United States / NCI NIH HHS / CA / 5U10-CA11488-19; United States / NCI NIH HHS / CA / 5U10-CA11488-20; United States / NCI NIH HHS / CA / 5U10-CA11488-21; United States / NCI NIH HHS / CA / 5U10-CA11488-22; United States / NCI NIH HHS / CA / 5U10-CA11488-23; United States / NCI NIH HHS / CA / 5U10-CA11488-24; United States / NCI NIH HHS / CA / 5U10-CA11488-25; United States / NCI NIH HHS / CA / 5U10-CA11488-26; United States / NCI NIH HHS / CA / 5U10-CA11488-27; United States / NCI NIH HHS / CA / 5U10-CA11488-28; United States / NCI NIH HHS / CA / 5U10-CA11488-29; United States / NCI NIH HHS / CA / 5U10-CA11488-30; United States / NCI NIH HHS / CA / 5U10-CA11488-31; United States / NCI NIH HHS / CA / 5U10-CA11488-32; United States / NCI NIH HHS / CA / 5U10-CA11488-33; United States / NCI NIH HHS / CA / 5U10-CA11488-34; United States / NCI NIH HHS / CA / 5U10-CA11488-35; United States / NCI NIH HHS / CA / 5U10-CA11488-36
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Philippet P; Otten J; Plouvier E; Béhar C; Boutard P; Millot F; Waterkeyn C; Velde IV; Solbu G
  •  go-up   go-down


54. Yao L, Chen Z, Cen J, Liang J, Feng Y, He J, Qi X, Shen H: The pattern of clonal immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Chinese adult acute lymphoblastic leukemia patients. Leuk Res; 2008 Nov;32(11):1735-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pattern of clonal immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Chinese adult acute lymphoblastic leukemia patients.
  • We have studied forty Chinese adult ALL patients at newly diagnosis, using standard primers and protocols of BIOMED-2 multiplex PCR, to determine the feasibility of Ig and TCR gene rearrangements as diagnostic and patient-specific MRD-RQ-PCR targets for molecular monitoring.
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor / genetics. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Genes, Immunoglobulin / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18456325.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


55. Yanada M, Kiyoi H, Murata M, Suzuki M, Iwai M, Yokozawa T, Baba H, Emi N, Naoe T: Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med; 2006;45(5):259-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia.
  • RESULTS: A total of 31 patients with acute leukemia who developed febrile neutropenia were enrolled in the study.
  • Underlying diseases consisted of acute myeloid leukemia (n=15) and acute lymphoblastic leukemia (n=3).
  • [MeSH-minor] Adolescent. Adult. Algorithms. Echinocandins. Female. Fever / etiology. Humans. Leukemia, Myeloid / complications. Lipopeptides. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Prospective Studies

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595990.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; 0 / Lipoproteins; 0 / Peptides, Cyclic; R10H71BSWG / micafungin
  •  go-up   go-down


56. Küker W, Bader P, Herrlinger U, Heckl S, Nägele T: Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI. J Neurooncol; 2005 May;73(1):47-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, acute neurotoxicity with confusion, disorientation, seizures and focal deficits has also been reported.
  • Because acute neurological symptoms in patients under chemotherapy for neoplastic disorders may have many reasons, MR-imaging is usually necessary to identify the underlying pathology.
  • We report on clinical and imaging findings of reversibly restricted diffusion in a patient with transient encephalopathy after intrathecal administration of MTX for recurrent acute lymphatic leukaemia.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Diseases / chemically induced. Methotrexate / adverse effects. Neurotoxicity Syndromes / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Mar 4;345(8949):544-7 [7776773.001]
  • [Cites] Stroke. 1997 May;28(5):1082-5 [9158653.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Sep-Oct;10(5):959-64 [2505541.001]
  • [Cites] Magn Reson Imaging. 2003 Jul;21(6):645-50 [12915196.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Oct;24(9):1887-90 [14561622.001]
  • [Cites] Ann Neurol. 1995 Feb;37(2):231-41 [7847864.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Oct;20(9):1636-41 [10543633.001]
  • [Cites] Neuroradiology. 2003 Oct;45(10):717-21 [12942223.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):101 [12764767.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):913-8 [7607965.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1176-81 [9697870.001]
  • [Cites] Med Pediatr Oncol. 2001 Jun;36(6):662-4 [11344503.001]
  • [Cites] Neurology. 2004 Mar 9;62(5):832-3 [15007149.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1997-2004 [1525778.001]
  • [Cites] Neuroradiology. 2003 Jul;45(7):493-7 [12761601.001]
  • [Cites] Radiology. 1991 Jul;180(1):205-9 [2052695.001]
  • (PMID = 15933817.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


57. Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, Iliopoulos D, Caligiuri MA, Huebner K, Croce CM: Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res; 2006 Jun 01;12(11 Pt 1):3494-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35.
  • Adenovirus 5 (Ad5) virus or adeno-associated viral vectors have been used to study the tumor suppressor function of FHIT in solid tumors, but these tools have not been effective in leukemias.
  • EXPERIMENTAL DESIGN: Infection efficiency of Ad5/F35-FHIT and Ad5/F35-GFP viruses was tested in leukemia cell lines that lacked FHIT expression, and biological effects of successful infection were assessed.
  • An acute myelogenous leukemia, a chronic myelogenous leukemia, and four acute lymphoblastic leukemia human cell lines were examined as well as two EBV-transformed B lymphoblastoid cell lines that expressed endogenous FHIT.
  • RESULTS: Two of four acute lymphoblastic leukemia cell lines, Jurkat and MV4;11, which were efficiently infected with Ad5/F35-FHIT, underwent growth suppression and massive induction of apoptosis without apparent activation of caspase-8 or caspase-2 and late activation of caspase-3.
  • The two remaining infected acute lymphoblastic leukemia cell lines, Molt-3 and RS4;11, were apparently unaffected.
  • Restoration of FHIT expression in the chronic myelogenous leukemia K562 cell line and the acute myelogenous leukemia KG1a cell line also induced apoptosis but at later time points than seen in the acute lymphoblastic leukemia Jurkat and MV4;11 cell lines. I.v. injection of Ad5/F35-FHIT-infected Jurkat cells resulted in abrogation of tumorigenicity in the NOD/SCID xenogeneic engraftment model.
  • CONCLUSION: FHIT restoration in some FHIT-deficient leukemia cells induces both antiproliferative and proapoptotic effects involving the intrinsic caspase apoptotic pathway.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Adenoviruses, Human / genetics. Gene Expression Regulation, Neoplastic / genetics. Genetic Therapy / methods. Leukemia / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / genetics. Cell Cycle. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Drug Screening Assays, Antitumor. Enzyme Inhibitors / pharmacology. Gene Transfer Techniques. Genetic Vectors / genetics. Green Fluorescent Proteins / genetics. Humans. Kinetics. Mice. Mice, Inbred NOD. Mice, SCID. Structure-Activity Relationship. Transplantation, Heterologous. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2016 Dec 15;22(24):6304 [27856602.001]
  • (PMID = 16740775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA56036; United States / NCI NIH HHS / CA / CA77738; United States / NCI NIH HHS / CA / CA78890; United States / NCI NIH HHS / CA / CA89341
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


58. Claviez A, Eckert C, Seeger K, Schrauder A, Schrappe M, Henze G, von Stackelberg A: Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. Haematologica; 2006 Feb;91(2):272-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
  • We treated three children with relapsed or refractory CD20 positive B-cell precursor acute lymphoblastic leukemia with rituximab in combination with chemotherapy, which produced a decreasing or persistent low positive minimal residual disease load.
  • Two children subsequently underwent allogeneic stem cell transplantation and remain in complete remission at days +399 and +332.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16461321.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


59. Eiser C, Davies H, Jenney M, Stride C, Glaser A: HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer; 2006 Jan;46(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL).
  • BACKGROUND: Dexamethasone is increasingly used as the steroid of choice in trials for standard risk children with acute lymphoblastic leukemia (ALL).
  • PROCEDURE: Standardized questionnaires to assess parent and child HRQOL at 3-6 months after diagnosis (T1) and 1 year later (T2) completed by mothers in family homes.
  • [MeSH-major] Anti-Inflammatory Agents / adverse effects. Dexamethasone / adverse effects. Health Status. Mental Health. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Health.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15926164.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 7S5I7G3JQL / Dexamethasone; VB0R961HZT / Prednisone
  •  go-up   go-down


60. Schmitz NM, Hirt A, Aebi M, Leibundgut K: Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia. Am J Pathol; 2006 Sep;169(3):1074-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia.
  • In Nalm-6 acute lymphoblastic leukemia extracts, serine 608 is phosphorylated by CDK4/6 complexes but not by CDK2.
  • Serine 612 phosphorylation by CDK4 also occurred in extracts of childhood acute lymphoblastic leukemia cells but not in extracts of mobilized CD34+ hemopoietic progenitor cells.
  • This phenomenon could contribute to the commitment of childhood acute lymphocytic leukemia cells to proliferate and explain their refractoriness to differentiation-inducing agents.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Cyclin-Dependent Kinase 2 / metabolism. Cyclin-Dependent Kinase 4 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Protein Processing, Post-Translational. Retinoblastoma-Like Protein p107 / metabolism
  • [MeSH-minor] Antigens, CD34. Cell Differentiation / drug effects. Cell Line, Tumor. Cell-Free System / metabolism. Drug Resistance, Neoplasm / drug effects. G1 Phase / drug effects. Hematopoietic Stem Cells / metabolism. Humans. Indoles / pharmacology. Multiprotein Complexes / metabolism. Phosphorylation / drug effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jan 27;19(4):562-70 [10698526.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4320-3 [10969768.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 7;275(3):877-84 [10973815.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19358-66 [12646568.001]
  • [Cites] Cell. 2003 Aug 22;114(4):431-43 [12941272.001]
  • [Cites] Nat Genet. 2003 Sep;35(1):25-31 [12923533.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4794-803 [12970191.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1775-85 [14561402.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):27-36 [14700606.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 7;317(3):779-86 [15081408.001]
  • [Cites] Cell. 2004 Apr 16;117(2):239-51 [15084261.001]
  • [Cites] Cell. 2004 Aug 20;118(4):477-91 [15315760.001]
  • [Cites] Cell. 2004 Aug 20;118(4):493-504 [15315761.001]
  • [Cites] Science. 1989 Nov 3;246(4930):603-8 [2683075.001]
  • [Cites] Cell. 1991 May 3;65(3):381-93 [2018973.001]
  • [Cites] Cell. 1991 Oct 18;67(2):293-302 [1655277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):6914-8 [8346196.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6501-8 [8413249.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • [Cites] Leukemia. 1994 Jun;8(6):940-5 [8207988.001]
  • [Cites] Cell. 1994 Jul 15;78(1):161-72 [8033208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3215-20 [8622916.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1093-106 [16360038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14317-22 [11114185.001]
  • [Cites] Leukemia. 2001 Jan;15(1):1-9 [11243375.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4773-84 [11416152.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):83-6 [11544530.001]
  • [Cites] EMBO Rep. 2001 Sep;2(9):794-9 [11520855.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):60-5 [12542976.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8313-20 [8626527.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):7173-81 [8943373.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7060-9 [9003781.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):249-54 [9010227.001]
  • [Cites] Br J Haematol. 1997 Feb;96(2):366-8 [9029026.001]
  • [Cites] Mol Biol Cell. 1997 Feb;8(2):287-301 [9190208.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12738-46 [9139732.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5771-83 [9315635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10699-704 [9380698.001]
  • [Cites] Oncogene. 1997 Dec 4;15(23):2855-66 [9419977.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):753-61 [9447971.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):765-9 [9635861.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10493-8 [9724731.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9463-71 [10092628.001]
  • [Cites] Pediatr Res. 1999 May;45(5 Pt 1):692-6 [10231867.001]
  • [Cites] Cell. 1999 Sep 17;98(6):859-69 [10499802.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):831-7 [15574337.001]
  • [Cites] J Biochem. 2005 Mar;137(3):381-6 [15809340.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):591-8 [15950907.001]
  • [Cites] Stem Cells. 2005 Aug;23(7):1002-11 [15941859.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):831-6 [16007079.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1400-6 [15878982.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1783-7 [16107892.001]
  • (PMID = 16936279.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Indoles; 0 / Multiprotein Complexes; 0 / Retinoblastoma-Like Protein p107; 114719-57-2 / fascaplysine; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ PMC1698824
  •  go-up   go-down


61. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadié M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC, GOELAMS and GEIL study: Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol; 2009 Jun;145(5):624-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.
  • The diagnosis of plasmacytoid dendritic cell leukaemia (pDCL) is based on the immunophenotypic profile: CD4(+) CD56(+) lineage(neg) CD45RA(+)/RO(neg) CD11c(neg) CD116(low) CD123(+) CD34(neg) CD36(+) HLA-DR(+).
  • This study aimed to validate pDCL-specific markers for diagnosis by flow-cytometry or quantitative reverse transcription polymerase chain reaction on bone marrow samples.
  • Expression of markers previously found in normal pDC was analysed in 16 pDCL, four pDCL presenting an atypical phenotype (apDCL) and 113 non-pDC - lymphoid or myeloid - acute leukaemia.
  • BDCA-2 was expressed on 12/16 pDCL and on 2/4 apDCL, but was never detected in the 113 non-pDC acute leukaemia cases.
  • BDCA-4 expression was found on 13/16 pDCL, but also in 12% of non-pDC acute leukaemia.
  • High levels of LILRA4 and TCL1A transcripts distinguished pDCL and apDCL from all other acute leukaemia (except B-cell acute lymphoblastic leukaemia for TCL1A).
  • We thus propose a diagnosis strategy, scoring first the CD4(+) CD56(+/-) MPO(neg) cCD3(neg) cCD79a(neg) CD11c(neg) profile and then the CD123(high), BDCA-2 and BDCA-4 expression.
  • Atypical pDCL can be also identified this way and non-pDC acute leukaemia excluded: this scoring strategy is useful for diagnosing pDCL and apDCL.
  • [MeSH-major] Algorithms. Dendritic Cells / immunology. Leukemia / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Child. Female. Flow Cytometry / methods. Humans. Interleukin-3 Receptor alpha Subunit / analysis. Lectins, C-Type / analysis. Leukemia, Myeloid, Acute / immunology. Male. Membrane Glycoproteins / analysis. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Proto-Oncogene Proteins / analysis. Receptors, Immunologic / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388928.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CLEC4C protein, human; 0 / Interleukin-3 Receptor alpha Subunit; 0 / LILRA4 protein, human; 0 / Lectins, C-Type; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Immunologic; 0 / TCL1A protein, human
  •  go-up   go-down


62. Wang SL, Zhao H, Zhou B, Chen YL, Zou Y, Zhu XF, Li QS, Han MZ, Yang RC, Han ZC: Polymorphisms in ERCC1 and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Leuk Res; 2006 Nov;30(11):1341-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in ERCC1 and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.
  • In this study, the relationship of two ERCC1 polymorphisms, 8092C>A and 19007G>A, with susceptibility to acute lymphoblastic leukemia (ALL) was investigated in 183 childhood patients.
  • [MeSH-major] DNA-Binding Proteins / genetics. Endonucleases / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723154.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  •  go-up   go-down


63. Campana D: Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):100-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease in acute lymphoblastic leukemia.
  • In patients with acute lymphoblastic leukemia (ALL), monitoring of minimal residual disease (MRD) offers a way to precisely assess early treatment response and detect relapse.
  • Hence, results of MRD studies can be used to select treatment intensity and duration, and to estimate the optimal timing for hematopoietic stem cell transplantation.
  • Practical issues in the implementation of MRD assays in clinical studies include determining the most informative time point to study MRD and the levels of MRD that will trigger changes in treatment intensity, as well as the relative cost and informative power of different methodologies.
  • The identification of new markers of leukemia and the use of increasingly refined assays should further facilitate routine monitoring of MRD and help to clarify the cellular and biologic features of leukemic cells that resist chemotherapy in vivo.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3046-50 [18565891.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Blood. 2006 Jul 1;108(1):97-102 [16537802.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):686-94 [11849234.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1952-8 [11877265.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Haematologica. 2007 May;92(5):612-8 [17488684.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1508-16 [10735899.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):481-9 [18710378.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:366-73 [19074112.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):227-37 [18492099.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1939-43 [11069029.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):275-81 [11167819.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1485-7 [11516112.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1982-4 [11535539.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):409-17 [11905735.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1432-6 [12145681.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):849-51 [14520434.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Lancet. 1980 May 24;1(8178):1144 [6154853.001]
  • [Cites] Leuk Res. 1981;5(4-5):301-9 [7026903.001]
  • [Cites] Blood. 1988 Jul;72(1):299-307 [3291983.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(15):5698-702 [3165197.001]
  • [Cites] Leukemia. 1988 Oct;2(10):628-33 [3172839.001]
  • [Cites] Leukemia. 1989 Feb;3(2):155-8 [2536129.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):5123-7 [2500663.001]
  • [Cites] Blood. 1989 Oct;74(5):1762-7 [2676018.001]
  • [Cites] Blood. 1990 Jul 1;76(1):163-71 [1973061.001]
  • [Cites] Anal Cell Pathol. 1990 Jul;2(4):229-40 [1703434.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1289-95 [8413409.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):196-200 [7904666.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1416-34 [7888664.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] Br J Haematol. 1997 Nov;99(2):314-9 [9375747.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):139-52 [10440852.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1971-80 [15470492.001]
  • [Cites] Leukemia. 2005 Jan;19(1):49-56 [15538405.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • (PMID = 19100372.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NCI NIH HHS / CA / P30 CA021765; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  • [Other-IDs] NLM/ NIHMS89417; NLM/ PMC2632881
  •  go-up   go-down


64. Brixey AG, Light RW: Pleural effusions due to dasatinib. Curr Opin Pulm Med; 2010 Jul;16(4):351-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Dasatinib is a novel tyrosine-kinase inhibitor approved for treatment of BCR-ABL positive chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) after imatinib failure.
  • A twice-daily dosing regimen was found to significantly correlate with development of effusions, and therefore once-daily dosing is now approved for treatment of chronic myeloid leukemia and acute lymphoblastic leukemia.
  • SUMMARY: Dasatinib is a promising agent for the treatment of refractory chronic myeloid leukemia and acute lymphoblastic leukemia.
  • [MeSH-minor] Clinical Trials as Topic. Dasatinib. Humans. Incidence. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Risk Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375898.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  • [Number-of-references] 27
  •  go-up   go-down


65. Styczynski J, Wysocki M, Debski R, Czyzewski K, Kolodziej B, Rafinska B, Kubicka M, Koltan S, Koltan A, Pogorzala M, Kurylak A, Olszewska-Slonina D, Balwierz W, Juraszewska E, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M, Kowalczyk J, Stefaniak J, Badowska W, Sonta-Jakimczyk D, Szczepanski T, Matysiak M, Malinowska I, Stanczak E, Wachowiak J, Konatkowska B, Gil L, Balcerska A, Maciejka-Kapuscinska L: Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol; 2007 Nov;133(11):875-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
  • PURPOSE: Cellular resistance in childhood acute leukemias might be related to profile and function of multidrug resistance proteins and apoptosis regulating proteins.
  • (2) correlation with ex vivo drug resistance, and (3) analysis of their prognostic impact on clinical outcome in childhood acute lymphoblastic (ALL) and acute myeloid (AML) leukemia.
  • Drug resistance for up to 30 anticancer agents was performed by the MTT assay.
  • CONCLUSIONS: The phenomenon of cellular drug resistance in childhood acute leukemias is multifactorial and plays an important role in response to therapy.
  • [MeSH-major] Drug Resistance, Multiple. Drug Resistance, Neoplasm. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Infant. Infant, Newborn. Male. Neoplasm Recurrence, Local / diagnosis. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Cancer Res Clin Oncol. 2007 Nov;133(11):895. Wachowiak, Jacek [added]; Konatkowska, Benigna [added]; Gil, Lidia [added]; Balcerska, Anna [added]; Maciejka-Kapuscinska, Lucyna [added]
  • [Cites] Med Pediatr Oncol. 2002 Jun;38(6):379-86 [11984797.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2253-8 [16158972.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3120-6 [11595704.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):45-9 [10695821.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3352-60 [12384437.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1224-9 [8035616.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2125-9 [16281077.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):85-95 [12691146.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):647-55 [9722289.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1864-9 [7475276.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4493-8 [12816874.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):264-79 [15491285.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):963-4 [14990658.001]
  • [Cites] Pediatr Int. 1999 Dec;41(6):641-7 [10618884.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2023-30 [10602424.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):195-9 [14752887.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2879-86 [11023525.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 1999 Nov;38(11):760-3 [11798719.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] Klin Padiatr. 2005 Nov-Dec;217(6):310-20 [16307416.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1843-8 [12685842.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1083-6 [12631611.001]
  • [Cites] Br J Haematol. 1999 Jun;105(4):876-82 [10554796.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2025-9 [16304569.001]
  • [Cites] Leuk Lymphoma. 1994 Apr;13(3-4):187-201 [8049644.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2117-24 [16107894.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Curr Opin Oncol. 1995 Jan;7(1):36-44 [7696362.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] Expert Rev Mol Diagn. 2004 Sep;4(5):705-13 [15347263.001]
  • [Cites] J Endocrinol. 2003 Jul;178(1):19-27 [12844332.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2002 Mar;41(3):183-5 [11940320.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8661-8 [16361551.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):599-604 [10404077.001]
  • [Cites] Sao Paulo Med J. 2004 Jul 1;122(4):166-71 [15543372.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):875-9 [12153178.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Ai Zheng. 2005 Aug;24(8):1015-7 [16086885.001]
  • [Cites] Exp Hematol. 1998 Nov;26(12):1111-7 [9808049.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2063-71 [16107896.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):321-7 [10050715.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1302-8 [12423683.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 17671794.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


66. Liu TB, Luo XF, Chen ZZ, Hu JD: [Effects of small interference RNA against c-myc on expression of c-myc and h-tert genes in acute lymphoblastic leukemia cell line Jurkat]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of small interference RNA against c-myc on expression of c-myc and h-tert genes in acute lymphoblastic leukemia cell line Jurkat].
  • This study was purposed to investigate the effect of small interfering RNA against c-myc on c-myc, h-tert gene and protein expressions in acute lymphoblastic leukemia cell line (Jurkat cells), so as to provide new methods and targets for gene therapy of leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129250.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Subunits; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Small Interfering; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


67. Yadav SP, Kalra M, Anjan M, Sachdeva A: Survival outcome in childhood acute lymphoblastic leukemia in India. Pediatr Blood Cancer; 2010 Jan;54(1):178; author reply 179
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival outcome in childhood acute lymphoblastic leukemia in India.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


68. Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB: Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol; 2008 Mar 1;26(7):1106-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
  • A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease.
  • We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Incidence. Infant. Infant, Newborn. Male. Razoxane / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18309945.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 68484
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 5AR83PR647 / Razoxane; 80168379AG / Doxorubicin
  •  go-up   go-down


69. Wilcken B: Improving child health--newborn screening for all? Ann Acad Med Singapore; 2008 Dec;37(12 Suppl):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the last 40 years newborn screening has been an undoubted success and many thousands of children have been saved from mental retardation and other problems because of early diagnosis of their disorders.


70. Gandemer V, Aubry M, Roussel M, Rio AG, de Tayrac M, Vallee A, Mosser J, Ly-Sunnaram B, Galibert MD: CD9 expression can be used to predict childhood TEL/AML1-positive acute lymphoblastic leukemia: proposal for an accelerated diagnostic flowchart. Leuk Res; 2010 Apr;34(4):430-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD9 expression can be used to predict childhood TEL/AML1-positive acute lymphoblastic leukemia: proposal for an accelerated diagnostic flowchart.
  • CD9 has been shown to be differentially expressed in childhood TEL/AML1-positive acute lymphoblastic leukemia (ALL).
  • Finally, we propose a faster procedure for optimizing the diagnosis of childhood BCP-ALL subgroups.
  • [MeSH-major] Antigens, CD / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Decision Support Techniques. Membrane Glycoproteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • [CommentIn] Leuk Res. 2010 Apr;34(4):418-9 [19892401.001]
  • (PMID = 19896186.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD9; 0 / Biomarkers, Tumor; 0 / CD9 protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Membrane Glycoproteins; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


71. Cheng KK: Oral mucositis: a phenomenological study of pediatric patients' and their parents' perspectives and experiences. Support Care Cancer; 2009 Jul;17(7):829-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-one percent of the children were diagnosed with acute lymphoblastic leukemia, and 36% were treated with methotrexate.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Support Care Cancer. 2007 Apr;15(4):427-40 [17131132.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):435-40 [16862549.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2007 Sep;10(5):627-31 [17693748.001]
  • [Cites] Support Care Cancer. 2004 Apr;12(4):268-73 [14750002.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):253-62 [12742264.001]
  • [Cites] Support Care Cancer. 2000 Jan;8(1):33-9 [10650895.001]
  • [Cites] Eur J Cancer. 2007 May;43(8):1269-75 [17383174.001]
  • [Cites] Res Nurs Health. 1999 Apr;22(2):177-85 [10094302.001]
  • [Cites] Oral Dis. 2006 May;12(3):229-41 [16700732.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1993 Jan;75(1):41-7 [8419873.001]
  • [Cites] J Pain Symptom Manage. 2000 Nov;20(5):374-87 [11068159.001]
  • [Cites] Clin Ther. 2007;29 Suppl:2547-61 [18164921.001]
  • [Cites] Support Care Cancer. 2001 Nov;9(8):575-80 [11762967.001]
  • [Cites] J Clin Nurs. 2007 Nov;16(11):2114-21 [17313536.001]
  • [Cites] Cancer Nurs. 2002 Dec;25(6):461-7; quiz 468-9 [12464838.001]
  • [Cites] J Pain Symptom Manage. 2001 Jun;21(6):498-505 [11397608.001]
  • [Cites] Cancer Nurs. 2003 Jun;26(3):222-9 [12832955.001]
  • [Cites] Spec Care Dentist. 2008 Mar-Apr;28(2):73-7 [18402621.001]
  • [Cites] Cancer Nurs. 1990 Dec;13(6):345-53 [2276107.001]
  • [Cites] Support Care Cancer. 2007 Jan;15(1):115-6; author reply 117 [16909245.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Feb;29(2):86-94 [17279004.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1208-16 [15110885.001]
  • [Cites] Cancer Nurs. 1992 Jun;15(3):196-205 [1611605.001]
  • [Cites] Oncol Nurs Forum. 2002 Aug;29(7):1051-7 [12183754.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):532-9 [16767731.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2590-8 [15602019.001]
  • [Cites] J Clin Nurs. 2003 Jul;12(4):562-70 [12790870.001]
  • (PMID = 19322593.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


72. Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M: Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. Int J Hematol; 2010 Oct;92(3):481-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.
  • Monitoring minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) is a useful way for assessing treatment response and relapse.
  • MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) with probes derived from fusion chimeric genes (BCR/ABL) (n = 12) or PCR-based detection of clonal immunoglobulin and T cell receptor gene rearrangements (n = 16), or both (n = 6).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Flow Cytometry. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction. Prognosis. Recurrence. Remission Induction. Stem Cell Transplantation. Survival Analysis. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 May;92(5):612-8 [17488684.001]
  • [Cites] Leukemia. 2010 Mar;24(3):521-35 [20033054.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):686-94 [11849234.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Acta Haematol. 2004;112(1-2):111-9 [15179011.001]
  • [Cites] Haematologica. 2005 Nov;90(11):1516-23 [16266899.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2115-20 [11264179.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):100-6 [19100372.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Oct;23(5):1083-98, vii [19825454.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):71-90 [11987917.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5251-6 [8652840.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Br J Haematol. 2010 Jan;148(1):80-9 [19863538.001]
  • [Cites] Acta Haematol. 2004;112(1-2):8-15 [15178999.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):227-37 [18492099.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] Am J Hematol. 2005 Nov;80(3):181-7 [16247752.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4153-62 [19141862.001]
  • [Cites] Leuk Res. 2009 Aug;33(8):1047-54 [19157547.001]
  • (PMID = 20830615.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


73. Speleman F, De Preter K, Hoebeeck J, Van Roy N, Vandesompele J: [New insights into the genetic basis of neuroblastoma]. Verh K Acad Geneeskd Belg; 2007;69(4):167-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Nieuwe inzichten in de genetische basis van neuroblastoom.
  • Neuroblastoma (NB) is, next to acute lymphoblastic leukaemia, brain tumours and lymphoma the most frequent paediatric tumour (8-10%).
  • A second important part of our work focussed on the gene expression profiling of NB precursor cells.
  • Gene expression analyses of model systems developed in our lab and of a large panel of cell lines and tumours allowed us to subtract a list of candidate genes which are now under further study.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17821957.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


74. Ociepa T, Maloney E, Kamieńska E, Wysocki M, Kurylak A, Matysiak M, Urasiński T, Urasińska E, Domagała W: Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia. Pol J Pathol; 2010;61(4):199-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.
  • Ineffective apoptosis is one of main causes of a treatment failure in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Leukocytes, Mononuclear / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prednisone / therapeutic use. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21290342.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; VB0R961HZT / Prednisone
  •  go-up   go-down


75. Jackson CC, Medeiros LJ, Miranda RN: 8p11 myeloproliferative syndrome: a review. Hum Pathol; 2010 Apr;41(4):461-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone marrow examination commonly is hypercellular, with or without eosinophilia, which usually leads to the initial diagnosis of a myeloproliferative neoplasm.
  • Lymph node biopsy in these patients has commonly shown lymphoblastic leukemia/lymphoma, most often reported as being of T-cell lineage, but bilineal myeloid/T-cell lymphomas and less often a myeloid sarcoma are also reported.
  • The natural history of this neoplasm is to evolve into acute leukemia, usually of myeloid or mixed lineage, and less frequently of T- or B-lymphoid lineage.
  • The prognosis is poor despite aggressive chemotherapy, with a few patients achieving long clinical remission after stem cell transplantation.
  • At the molecular level, all cases carry a chromosomal abnormality involving the fibroblast growth factor receptor 1 (FGFR1) gene at chromosome 8p11, where 10 translocations and 1 insertion have been identified.
  • In the current World Health Organization classification, the 8p11 myeloproliferative syndrome is designated as "myeloid and lymphoid neoplasms with FGFR1 abnormalities. "
  • [MeSH-minor] Diagnosis, Differential. Humans. Receptor, Fibroblast Growth Factor, Type 1 / genetics. Translocation, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc.
  • (PMID = 20226962.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  • [Number-of-references] 81
  •  go-up   go-down


76. Kuroki F, Goto H, Yanagimachi M, Kajiwara R, Fujii H, Isaki S, Takahashi H, Ikuta K, Yokota S: [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation]. Rinsho Ketsueki; 2006 Jul;47(7):639-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
  • We report the clinical courses of two cases with relapsed acute lymphoblastic leukemia (ALL) after allogeneic bone marrow transplantation (BMT).
  • After reinduction chemotherapy, the patients received reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells harvested from their previous BMT donors.
  • Graft-versus-host disease (GVHD) prophylaxis was performed with low dose cyclosporin A (CsA, 1 mg/kg/day d.i.v.) on its own.
  • Since acute GVHD had not developed by day 30, CsA was stopped abruptly in both cases.
  • After CsA withdrawal, acute GVHD developed, and subsequent chronic GVHD.
  • One of two cases is alive without any relapse of the leukemia 40 months after the peripheral blood stem cell transplantation (PBSCT).
  • In both these cases, the results suggest that using PBSC as a stem cell source and abrupt cessation of GVHD prophylaxis provided a potent graft-versus-leukemia effect.
  • [MeSH-major] Bone Marrow Transplantation. Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tissue Donors. Transplantation Conditioning
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Cyclosporine / administration & dosage. Graft vs Host Disease / prevention & control. Humans. Infant. Male. Melphalan / administration & dosage. Recurrence. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910574.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 83HN0GTJ6D / Cyclosporine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


77. Kumagai T, Müller CI, Desmond JC, Imai Y, Heber D, Koeffler HP: Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines. Leuk Res; 2007 Apr;31(4):523-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines.
  • S.B inhibited the growth of ALL, lymphoma and myeloma cell lines by inducing apoptosis and cell cycle arrest at clinically achievable concentrations.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Apoptosis / drug effects. Cell Proliferation / drug effects. Drugs, Chinese Herbal / therapeutic use. Multiple Myeloma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Scutellaria baicalensis / chemistry
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Colony-Forming Units Assay. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Drug Screening Assays, Antitumor. Flavonoids / therapeutic use. Flow Cytometry. Humans. Membrane Potential, Mitochondrial / drug effects. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007926.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / Flavonoids; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 347Q89U4M5 / baicalin
  •  go-up   go-down


78. Mittal MK: Severe hypercalcemia as a harbinger of acute lymphoblastic leukemia. Pediatr Emerg Care; 2007 Jun;23(6):397-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypercalcemia as a harbinger of acute lymphoblastic leukemia.
  • A few days later, she developed pancytopenia when her bone marrow biopsy specimen established the diagnosis of acute lymphoblastic leukemia.
  • It can be a harbinger of acute lymphoblastic leukemia.
  • Normal complete blood cell count at presentation does not exclude the diagnosis of leukemia.
  • [MeSH-major] Hypercalcemia / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572525.001).
  • [ISSN] 1535-1815
  • [Journal-full-title] Pediatric emergency care
  • [ISO-abbreviation] Pediatr Emerg Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Bernard N, Alberdi AJ, Tanguy ML, Brugere H, Helissey P, Hubert C, Gendrey N, Guillosson JJ, Nafziger J: Assessing the potential leukemogenic effects of 50 Hz magnetic fields and their harmonics using an animal leukemia model. J Radiat Res; 2008 Nov;49(6):565-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the potential leukemogenic effects of 50 Hz magnetic fields and their harmonics using an animal leukemia model.
  • To answer the still unresolved question of the possible leukemogenic effects of extremely low frequency magnetic fields (ELF-MFs) and of their harmonics on the incidence of B acute lymphoblastic leukemia in children, we used an animal model to explore the possible co-initiating or co-promoting effects of ELF-MFs on the development of leukemia.
  • We used a rat model in which B acute lymphoblastic leukemia is chemically induced by a nitrosurea derivative.
  • We compared body weight and survival time, percentage of bone marrow blast cells, cumulative incidence of leukemia and type of leukemia in the unexposed groups and in the groups exposed to 50 Hz MFs, with and without harmonics.
  • Significant changes in the leukemia type obtained after gamma-irradiation of the leukemia model, showed its sensitivity to a physical agent.
  • Our results do not support the hypothesis that ELF-MFs, with or without harmonics, affect the development of B acute lymphoblastic leukemia in children.
  • [MeSH-major] Leukemia, Radiation-Induced / etiology. Leukemia, Radiation-Induced / physiopathology. Risk Assessment / methods. Whole-Body Irradiation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838845.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


80. Allard A, Haddy N, Le Deley MC, Rubino C, Lassalle M, Samsaldin A, Quiniou E, Chompret A, Lefkopoulos D, Diallo I, de Vathaire F: Role of radiation dose in the risk of secondary leukemia after a solid tumor in childhood treated between 1980 and 1999. Int J Radiat Oncol Biol Phys; 2010 Dec 1;78(5):1474-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiation dose in the risk of secondary leukemia after a solid tumor in childhood treated between 1980 and 1999.
  • PURPOSE: The purpose of this study was to estimate the risk of secondary leukemia as a function of radiation dose, taking into account heterogeneous radiation dose distribution.
  • METHODS AND MATERIALS: We analyzed a case-control study that investigated the risk of secondary leukemia and myelodysplasia after a solid tumor in childhood; it included 61 patients with leukemia matched with 196 controls.
  • RESULTS: Whatever the model, we failed to evidence a role for the radiation dose to active bone marrow in the risk of later leukemia, myelodysplasia, or myeloproliferative syndrome, when adjusting for epipodophyllotoxin and anthracycline doses.
  • This result was confirmed when fitting models that included total dose of radiation delivered during radiotherapy, when fitting models taking into account dose per fraction, and when restricting the analysis to acute myeloid leukemia.
  • CONCLUSIONS: In contrast to results found in similar studies that included children treated before the use of epipodophyllotoxins, this study failed to show a role for radiotherapy in the risk of secondary leukemia after childhood cancer in children treated between 1980 and 1999.
  • [MeSH-major] Bone Marrow / radiation effects. Leukemia, Radiation-Induced / etiology. Myelodysplastic Syndromes / etiology. Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Algorithms. Anthracyclines / administration & dosage. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Case-Control Studies. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. France. Humans. Infant. Infant, Newborn. Leukemia, Myeloid, Acute. Likelihood Functions. Male. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / etiology. Podophyllotoxin / administration & dosage. Podophyllotoxin / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Radiotherapy Dosage. Risk Assessment

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20303670.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


81. Tang Y, Xu X, Song H, Yang S, Shi S, Wei J: Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer; 2008 Sep;51(3):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of childhood acute lymphoblastic leukemia treated in China.
  • RESULTS: Among the 346 newly diagnosed patients, 167 (48.3%) stopped treatment either at diagnosis or during therapy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Treatment Failure. Treatment Refusal

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18506765.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Mejía Aranguré JM, Flores Aguilar H, Juárez Muñoz I, Vázquez Langle J, Games Eternod J, Pérez Saldívar ML, Ortega Alvarez MC, Rendón Macías ME, Gutiérrez AF: [Age of onset of different malignant tumors in childhood]. Rev Med Inst Mex Seguro Soc; 2005 Jan-Feb;43(1):25-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Age of onset of different malignant tumors in childhood].
  • [Transliterated title] Edad de aparición de los diferentes tumores malignos en la infancia.
  • OBJECTIVE: To identify the main age of onset of different malignant tumors in childhood and to describe the distribution of the different tumors in each pediatric age group.
  • RESULTS: Peak ages for hepatic, sympathetic nervous system, germ cell tumors, retinoblastoma and rhabdomyosarcoma were between 2 and 3 years of age.
  • Wilms' tumor appeared between the first and fourth years; central nervous system tumors between 4 and 5 years; acute lymphoblastic leukemia between 2 and 4 years; non-Hodgkin's lymphomas between 3 and 6 years; Hodgkin's disease between 4 and 8 years; bone tumors between 10 and 14 years.
  • In acute myeloid leukemia and carcinomas no age peak was found.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998478.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


83. Panis B, Vlaar AM, van Well GT, Granzen B, Weber JW, Postma AA, Klinkenberg S: Posterior reversible encephalopathy syndrome in paediatric leukaemia. Eur J Paediatr Neurol; 2010 Nov;14(6):539-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior reversible encephalopathy syndrome in paediatric leukaemia.
  • This report describes four patients with acute lymphoblastic leukaemia, suffering from posterior reversible encephalopathy syndrome during the induction period of treatment.
  • A review of the literature on posterior reversible encephalopathy syndrome in paediatric leukaemia is given.
  • All patients in this case series presented after introduction of the new induction protocol for acute lymphoblastic leukaemia.
  • It is important to consider this diagnosis during the induction phase of leukaemia treatment in the presence of neurological symptoms.
  • [MeSH-major] Brain Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
  • [CommentIn] Eur J Paediatr Neurol. 2011 Mar;15(2):182 [20810297.001]
  • (PMID = 20171912.001).
  • [ISSN] 1532-2130
  • [Journal-full-title] European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • [ISO-abbreviation] Eur. J. Paediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents
  •  go-up   go-down


84. Pais AP, Amare Kadam PS, Raje GC, Banavali S, Parikh P, Kurkure P, Arora B, Gujral S, Kumar SA, Badrinath Y: RUNX1 aberrations in ETV6/RUNX1-positive and ETV6/RUNX1-negative patients: its hemato-pathological and prognostic significance in a large cohort (619 cases) of ALL. Pediatr Hematol Oncol; 2008 Sep;25(6):582-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A large-cohort study (619) of acute lymphoblastic leukemia (ALL) revealed an ETV6/RUNX1 (previously known as TEL/AML1) incidence of 18% in pediatric B-cell precussor ALL, indicating no geographical heterogeinity.
  • Additional genetic changes, such as ETV6 loss, extra RUNX1, ETV6/RUNX1 duplication, and MLL aberrations in the ETV6/RUNX1-positive group, supported the hypothesis of the ETV6/RUNX1 leukemogenic model that these secondary changes are necessary for leukemogenesis rather than progression of disease.
  • This study disclosed RUNX1 alterations in the ETV6/RUNX1-negative group of BCP-ALL that encourages the investigation of RUNX1 at a large scale with longer follow-up, which will focus on the prognostic importance and the underlying biology of disease.
  • [MeSH-major] Chromosome Aberrations. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728978.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins
  •  go-up   go-down


85. Nath CE, Dallapozza L, Eslick AE, Misra A, Carr D, Earl JW: An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia. Biomed Chromatogr; 2009 Feb;23(2):152-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
  • A novel assay for the determination of l-asparaginase activity in human plasma is described that is based on the HPLC quantitation of l-aspartic acid produced during enzyme incubation.
  • The l-asparaginase assay was linear from 0.1 to 10 U/mL activity and interday precision and accuracy were less than 13%.
  • The assay utility was established in 12 children who received E. coli l-asparaginase as treatment for acute lymphoblastic leukaemia.
  • [MeSH-major] Antineoplastic Agents / metabolism. Asparaginase / metabolism. Asparagine / metabolism. Chromatography, High Pressure Liquid / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18823071.001).
  • [ISSN] 1099-0801
  • [Journal-full-title] Biomedical chromatography : BMC
  • [ISO-abbreviation] Biomed. Chromatogr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Escherichia coli Proteins; 0RH81L854J / Glutamine; 30KYC7MIAI / Aspartic Acid; 3KX376GY7L / Glutamic Acid; 6KA95X0IVO / Homoserine; 7006-34-0 / Asparagine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


86. Zhang WY, Long YX, Fu GN: [Congenital acute lymphocytic leukemia ALL-2 in a 9-hour old newborn infant]. Zhonghua Er Ke Za Zhi; 2006 Mar;44(3):238
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Congenital acute lymphocytic leukemia ALL-2 in a 9-hour old newborn infant].
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / congenital

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624070.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


87. Abdelhaleem M, Sun TH, Ho M: DHX32 expression suggests a role in lymphocyte differentiation. Anticancer Res; 2005 Jul-Aug;25(4):2645-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DHX32 message was down-regulated in acute lymphoblastic leukemia cell lines and patient samples.
  • [MeSH-minor] Cell Differentiation / physiology. Flow Cytometry. Humans. Immunohistochemistry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Thymus Gland / cytology. Thymus Gland / enzymology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080506.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.6.4.13 / RNA Helicases
  •  go-up   go-down


88. Brouwer C, Vogels-Mentink TM, Keizer-Garritsen JJ, Trijbels FJ, Bökkerink JP, Hoogerbrugge PM, van Wering ER, Veerman AJ, De Abreu RA: Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment. Clin Chim Acta; 2005 Nov;361(1-2):95-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment.
  • At the optimal pH, assays were performed to establish Km and Vmax values.
  • [MeSH-major] 5'-Nucleotidase / metabolism. 6-Mercaptopurine / therapeutic use. Guanosine Monophosphate / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Sulfhydryl Compounds / chemistry. Thioguanine / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990089.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Sulfhydryl Compounds; 85-32-5 / Guanosine Monophosphate; E7WED276I5 / 6-Mercaptopurine; EC 3.1.3.5 / 5'-Nucleotidase; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


89. Essa EA, El Halim SM, Abo-Elenin A, El Bendary A, Abdou SH, Farag W: Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia. Egypt J Immunol; 2007;14(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia.
  • Proliferation of malignant lymphohematopoietic cells is thought to be regulated by a number of surface molecules on tumour cells whose expression may contribute to neoplastic transformation.
  • In this work, reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect the gene expression (mRNA) of CD30 variant (CD30v) and CD30 Ligand (CD30L) on the peripheral blood mononuclear cells (PBMCs) of 15 healthy individuals as a control group, 15 patients with newly diagnosed acute myeloid leukemia (AML) and 15 patients with newly diagnosed acute lymphocytic leukemia (ALL).
  • Patients with positive expression of CD30v and CD30L were found to have significantly increased blast cell % (p<0.001), increased total leucocytic count (P<0.001) and decreased platelets count (P<0.001) than those with negative expression.
  • As regard to immunophenotypes of ALL, positive expression was found to be significantly higher in B-cell than T-cell subtype (77.8% versus 16.7%, P=0.02).
  • Positive expression was also significantly associated with more aggressive disease and with B-cell than T-cell subtypes.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689277.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / CD30 Ligand; 0 / RNA, Messenger
  •  go-up   go-down


90. Mandal C, Srinivasan GV, Chowdhury S, Chandra S, Mandal C, Schauer R, Mandal C: High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status. Glycoconj J; 2009 Jan;26(1):57-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status.
  • Previous studies had established an over-expression of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).
  • Here, we report the discovery and characterization of sialate-O-acetyltransferase enzyme in ALL-cell lines and lymphoblasts from bone marrow of children diagnosed with B- and T-ALL.
  • Sialate-O-acetyltransferase activity in cell lysates or microsomal fractions of lymphoblasts of patients was always higher than that in healthy donors reaching up to 22-fold in microsomes.
  • Sialate-O-acetyltransferase activity increased at the diagnosis of leukaemia, decreased with clinical remission and sharply increased again in relapsed patients as determined by radiometric-assay.
  • [MeSH-major] Acetyltransferases / metabolism. Bone Marrow / enzymology. Microsomes / enzymology. Neoplasm Proteins / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • [MeSH-minor] Acetyl Coenzyme A / metabolism. Adolescent. Cell Line, Tumor. Child. Child, Preschool. Cytidine Monophosphate / metabolism. Humans. Infant. Male. N-Acetylneuraminic Acid / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Feb;13(2):309-12 [10025909.001]
  • [Cites] Biol Chem. 2004 Feb;385(2):145-52 [15101557.001]
  • [Cites] Biochim Biophys Acta. 1961 Sep 16;52:349-60 [14477442.001]
  • [Cites] Eur J Biochem. 2004 Jan;271(2):281-90 [14717696.001]
  • [Cites] Int Immunol. 2005 Feb;17(2):177-91 [15629900.001]
  • [Cites] Cancer Res. 1990 Mar 1;50(5):1403-10 [2302705.001]
  • [Cites] Zoology (Jena). 2004;107(1):49-64 [16351927.001]
  • [Cites] Glycoconj J. 2006 Dec;23(9):627-38 [17115281.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15130-8 [8662976.001]
  • [Cites] Glycoconj J. 2000 Jul-Sep;17(7-9):485-99 [11421344.001]
  • [Cites] Glycoconj J. 2007 Jan;24(1):17-24 [17146715.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Glycoconj J. 1998 Sep;15(9):895-904 [10052593.001]
  • [Cites] J Biol Chem. 1988 Feb 5;263(4):2079-86 [3339003.001]
  • [Cites] Biochem Z. 1958;329(6):490-507 [13535603.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):254-60 [11180001.001]
  • [Cites] Hoppe Seylers Z Physiol Chem. 1982 Mar;363(3):255-62 [7076126.001]
  • [Cites] J Biol Chem. 1981 Jan 25;256(2):989-93 [7451485.001]
  • [Cites] Carbohydr Res. 1995 Mar 1;268(1):115-25 [7736461.001]
  • [Cites] Br J Haematol. 2005 Jan;128(1):35-41 [15606547.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):801-12 [11054061.001]
  • [Cites] Glycobiology. 2004 Oct;14(10):859-70 [15190007.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):270-7 [15197782.001]
  • [Cites] Biol Chem. 2007 Mar;388(3):297-306 [17338637.001]
  • [Cites] Glycoconj J. 1999 Jun;16(6):307-17 [10579699.001]
  • [Cites] Methods Enzymol. 1994;230:168-99 [8139495.001]
  • [Cites] J Biochem. 1998 Jul;124(1):111-21 [9644253.001]
  • [Cites] J Biol Chem. 1979 Feb 10;254(3):789-95 [83994.001]
  • [Cites] Chem Rev. 2002 Feb;102(2):439-69 [11841250.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1535-41 [12486096.001]
  • [Cites] Leukemia. 1999 Jan;13(1):119-25 [10049046.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5165-71 [8912852.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10197-206 [8486687.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):162-6 [2757191.001]
  • [Cites] J Biol Chem. 1985 Jun 10;260(11):6600-8 [3997840.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):7825-33 [16434401.001]
  • [Cites] Biochimie. 1998 Jan;80(1):49-57 [9587662.001]
  • [Cites] Eur J Biochem. 1981 Jun;117(1):41-55 [7262089.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Oct 26;362(3):651-7 [17761143.001]
  • (PMID = 18677580.001).
  • [ISSN] 1573-4986
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 72-89-9 / Acetyl Coenzyme A; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / N-acylneuraminate-9(7)-O-acetyltransferase; F469818O25 / Cytidine Monophosphate; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


91. Linabery AM, Ross JA: Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer; 2008 Nov 1;113(9):2575-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Five-year survival rates increased significantly overall (1975-1979: 63% vs 1995-1999: 79%; P< .0001) and for nearly all histologic types examined; increases were greatest for ependymoma (+37%; P< .0001) and non-Hodgkin lymphoma (+34%; P< .0001).
  • Hispanic children and adolescents had somewhat poorer 5-year rates than non-Hispanic whites overall (74% vs 81%; P< .0001) and for Ewing sarcoma, leukemia, central nervous system tumors, and melanoma.
  • The largest improvements were noted for acute lymphoblastic leukemia (+19%; P< .0001) and non-Hodgkin lymphoma (+19%; P< .0001).

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2004 Dec;15(10):1027-34 [15801487.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2097-105 [15589307.001]
  • [Cites] Cancer J. 2005 Jul-Aug;11(4):340-54 [16197724.001]
  • [Cites] BMJ. 2005 Dec 3;331(7528):1295 [16299015.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1162-8 [16429450.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):578-81 [16537719.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1711-42 [16958083.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):177-87 [17219013.001]
  • [Cites] CA Cancer J Clin. 2007 Jul-Aug;57(4):242-55 [17626120.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1070-3 [17943956.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1074-82 [17943961.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):288-98 [18354417.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1339-45 [12599243.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] Curr Opin Pediatr. 2004 Feb;16(1):9-14 [14758108.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):269-80 [15059650.001]
  • [Cites] J Pediatr Oncol Nurs. 2004 May-Jun;21(3):123-7 [15296038.001]
  • [Cites] Biometrics. 1983 Dec;39(4):941-8 [6671129.001]
  • [Cites] JAMA. 1995 Feb 22;273(8):633-7 [7844873.001]
  • [Cites] Epidemiol Rev. 1994;16(2):243-72 [7713179.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2343-50 [8635041.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):201-7 [8630931.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):759-65 [8980180.001]
  • [Cites] J Adolesc Health. 1997 Dec;21(6):366-73 [9401854.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • (PMID = 18837040.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA099936-04; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / T32 CA099936-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS70883; NLM/ PMC2765225
  •  go-up   go-down


92. Eyrich M, Wiegering V, Lim A, Schrauder A, Winkler B, Schlegel PG: Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients. Br J Haematol; 2009 Nov;147(3):360-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients.
  • Multidrug chemotherapy is a highly effective treatment for paediatric acute lymphoblastic leukaemia (ALL), but at the same time compromises immunity of patients.
  • Immune function in a homogenous cohort of 20 children with standard- and intermediate-risk ALL was analysed by immunophenotyping, intracellular cytokine staining, assessment of serum cytokine concentrations, T-cell receptor (TCR) repertoire diversity and thymic function.
  • This recovery was paralleled by a relative increase in naive IgM(+)IgD(+)CD27(-) B-cells, indicating de novo B-cell generation as the major pathway for B-cell reconstitution.
  • Our data show that during chemotherapy in standard- and intermediate-risk paediatric ALL patients the T-cell system remains relatively well preserved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adolescent. B-Lymphocyte Subsets / drug effects. B-Lymphocyte Subsets / immunology. Child. Child, Preschool. Cytokines / biosynthesis. Cytokines / blood. Female. Genetic Variation. Humans. Immunity, Cellular / drug effects. Immunophenotyping. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Lymphocyte Count. Male. Prospective Studies. Receptors, Antigen, T-Cell / genetics. T-Lymphocyte Subsets / drug effects. T-Lymphocyte Subsets / immunology. Thymus Gland / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694715.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


93. Shi JM, Huang H, Chen QF, Lin MF: [Expression level of TRF1 protein in human acute leukemia and its relationship with activity of telomerase]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):858-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression level of TRF1 protein in human acute leukemia and its relationship with activity of telomerase].
  • The study was aimed to investigate the expression level of TRF1 protein in human acute leukemia and relationship between expression level of TRF1 protein and activity of telomerase.
  • 20 cases of acute leukemias were studied when 11 normal volunteer's bone marrow was used as control.
  • The results showed that the expression level of TRF1 protein in normal bone marrow (2.217 +/- 0.461 microg/microl) was significantly higher than that in bone marrow of acute leukemia patients (0.754 +/- 0.343 microg/microl) (P < 0.01).
  • It was confirmed that the activity of telomerase in normal bone marrow was lower than that in bone marrow of acute leukemia patients (0.125 +/- 0.078 microg/microl vs 0.765 +/- 0.284 microg/microl, P < 0.01).

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096876.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Telomeric Repeat Binding Protein 1; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


94. Xu SN, Chen JP: [Research advance on the pathogenesis of T-ALL induced by notch 1 activating mutations]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb;18(1):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T-cell acute lymphoblastic leukemia (T-ALL) is the hematological malignancy of bone marrow characterized by the rapid proliferation and subsequent accumulation of immature T lymphocyte and mainly occurs in children and adolescents.
  • This review briefly discusses the four main subtypes of Notch 1 activating mutations, also focuses on how these mutations change the normal signaling pathways and genes expression during their participation in the pathogenesis of T-ALL, and how these insights will promote the development of newly targeting therapies for patients with this aggressive form of leukemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137156.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptor, Notch1
  •  go-up   go-down


95. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J: Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood; 2010 Jul 1;115(26):5428-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Mutation / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein Kinase Inhibitors / therapeutic use


96. Ness KK, Baker KS, Dengel DR, Youngren N, Sibley S, Mertens AC, Gurney JG: Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Dec;49(7):975-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia.
  • We compared body composition, muscle strength, and mobility between 75 adult survivors of childhood acute lymphoblastic leukemia (ALL) and expected values based on population normative data.
  • [MeSH-major] Body Composition. Mobility Limitation. Muscle Weakness. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Survivors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17091482.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA106778; United States / NCI NIH HHS / CA / CA55727; United States / NCI NIH HHS / CA / CA85503; United States / NCRR NIH HHS / RR / M01-RR00400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


97. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, van der Voort E, Valsecchi MG, de Lorenzo P, Sallan SE, Armstrong SA, Pieters R: Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood; 2005 Oct 1;106(7):2484-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) in infants is characterized by rearrangements of the mixed lineage leukemia (MLL) gene, drug resistance, and a poor treatment outcome.
  • [MeSH-major] Gene Rearrangement. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis. Binding Sites. Cell Line, Tumor. DNA / chemistry. DNA / metabolism. DNA Mutational Analysis. DNA Primers / chemistry. Dose-Response Relationship, Drug. Drug Resistance. Enzyme Inhibitors / pharmacology. Gene Duplication. Humans. Immunoprecipitation. In Situ Hybridization, Fluorescence. Infant. Infant, Newborn. Ligands. Mutation. Phosphorylation. Prognosis. RNA / chemistry. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Staurosporine / analogs & derivatives. Staurosporine / pharmacology. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956279.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / Enzyme Inhibitors; 0 / Ligands; 0 / Tetrazolium Salts; 0 / Thiazoles; 120685-11-2 / 4'-N-benzoylstaurosporine; 298-93-1 / thiazolyl blue; 63231-63-0 / RNA; 9007-49-2 / DNA; H88EPA0A3N / Staurosporine
  •  go-up   go-down


98. Kazemi T, Asgarian-Omran H, Memarian A, Shabani M, Sharifian RA, Vossough P, Ansaripour B, Rabbani H, Shokri F: Low representation of Fc receptor-like 1-5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia. Cancer Immunol Immunother; 2009 Jun;58(6):989-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low representation of Fc receptor-like 1-5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia.
  • Recent studies have demonstrated expression of Fc receptor-like (FCRL) molecules, a newly identified family with preferential B-cell lineage expression, in some chronic B-cell leukemias with possible implication for classification and/or targeted immunotherapy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Cell Surface / genetics. Receptors, Fc / genetics. Receptors, Immunologic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18802695.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / FCRL2 protein, human; 0 / FCRL4 protein, human; 0 / FCRL5 protein, human; 0 / FCRLA protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Fc; 0 / Receptors, Immunologic
  •  go-up   go-down


99. Karremann M, Schreiner U, Büsing KA, von Komorowski G, Dürken M: [Acute lymphoblastic leukemia presenting without peripheral blasts but with osteolysis and hypercalcemia in an adolescent. Atypical but not rare]. Orthopade; 2009 Aug;38(8):752-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia presenting without peripheral blasts but with osteolysis and hypercalcemia in an adolescent. Atypical but not rare].
  • Joint pain is one of the major symptoms in early leukemia.
  • Acute lymphoblastic leukemia was diagnosed, but the laboratory workup and radiologic imaging revealed atypical results.
  • Particularly in early precursor B-cell acute lymphoblastic leukemia, comparable initial symptoms and signs have been reported in adolescents; therefore, we recommend performing a bone marrow aspiration early on in cases of suspected osteolytic bone lesions.
  • [MeSH-major] Hypercalcemia / complications. Hypercalcemia / diagnosis. Osteolysis / complications. Osteolysis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Blast Crisis / complications. Blast Crisis / diagnosis. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2007 Oct;139(1):2 [17711516.001]
  • [Cites] J Pediatr Orthop. 2008 Jan-Feb;28(1):20-8 [18157042.001]
  • [Cites] J Pediatr Orthop B. 2005 May;14 (3):156-61 [15812284.001]
  • [Cites] Leukemia. 2007 Feb;21(2):288-96 [17183364.001]
  • [Cites] Pediatr Radiol. 1990;20(3):179-83 [2352796.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):990-3 [16496289.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1846-8 [11100075.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jul;43(1):66-9 [15170892.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):256-60 [8508415.001]
  • [Cites] Postgrad Med J. 1993 Jun;69(812):483-5 [8208650.001]
  • (PMID = 19533085.001).
  • [ISSN] 1433-0431
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


100. Schult C, Dahlhaus M, Ruck S, Sawitzky M, Amoroso F, Lange S, Etro D, Glass A, Fuellen G, Boldt S, Wolkenhauer O, Neri LM, Freund M, Junghanss C: The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer; 2010;10:560
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.
  • The multikinase inhibitor Sorafenib has antitumor activity in solid tumors and its effects on acute lymphoblastic leukemia (ALL) cells are still unclear.
  • METHODS: ALL cell lines (SEM, RS4;11 and Jurkat) were treated with Sorafenib alone or in combination with cytarabine, doxorubicin or RAD001.
  • Cell count, apoptosis and necrosis rates, cell cycle distribution, protein phosphorylation and metabolic activity were determined.
  • RESULTS: Sorafenib inhibited the proliferation of ALL cells by cell cycle arrest accompanied by down-regulation of CyclinD3 and CDK4.
  • CONCLUSION: Sorafenib displays significant antileukemic activity in vitro by inducing cell cycle arrest and apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis. B-Lymphocytes / pathology. Benzenesulfonates / pharmacology. Caspase 3 / metabolism. Caspase 7 / metabolism. Poly(ADP-ribose) Polymerases / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Pyridines / pharmacology. T-Lymphocytes / pathology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Humans. Jurkat Cells. Niacinamide / analogs & derivatives. Phenylurea Compounds. Phosphorylation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Pharm Des. 2002;8(25):2255-7 [12369853.001]
  • [Cites] Leukemia. 2007 Mar;21(3):439-45 [17205056.001]
  • [Cites] Trends Biochem Sci. 2003 Sep;28(9):488-94 [13678960.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1085-8 [14504097.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Leuk Res. 2007 May;31(5):673-82 [17007924.001]
  • [Cites] Blood. 2007 May 1;109(9):3676-8 [17213285.001]
  • [Cites] Cancer. 2007 May 15;109(10):2068-76 [17429836.001]
  • [Cites] Mol Cancer Ther. 2007 Sep;6(9):2449-57 [17766837.001]
  • [Cites] Blood. 2008 Jan 1;111(1):379-82 [17878402.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):535-48 [18026728.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 6;100(3):184-98 [18230792.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2312-9 [18391973.001]
  • [Cites] Leukemia. 2008 Apr;22(4):808-18 [18200035.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5124-30 [18698030.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1698-706 [18548104.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8022-30 [18829560.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(4):579-87 [19101137.001]
  • [Cites] J Cell Physiol. 2009 Jul;220(1):214-21 [19288493.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6567-71 [19389879.001]
  • [Cites] Breast Cancer Res Treat. 2009 Sep;117(2):243-51 [18807177.001]
  • [Cites] J Hepatol. 2009 Oct;51(4):725-33 [19665249.001]
  • [Cites] Mol Cancer Ther. 2010 Mar;9(3):742-50 [20197401.001]
  • [Cites] Mol Cancer Ther. 2010 Apr;9(4):953-62 [20371721.001]
  • [Cites] Int J Clin Exp Pathol. 2010;3(4):408-15 [20490331.001]
  • [Cites] Breast Cancer Res Treat. 2010 Nov;124(1):79-88 [20054642.001]
  • [Cites] Biochem J. 2004 Jun 1;380(Pt 2):297-309 [15005655.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):908-13 [15917664.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6861-9 [16007148.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7410-25 [16288288.001]
  • [Cites] Drugs Today (Barc). 2005 Dec;41(12):773-84 [16474853.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2522-30 [17041096.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2676-84 [17121914.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:178-84 [17124058.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11851-8 [17178882.001]
  • [Cites] Leukemia. 2007 Feb;21(2):333-9 [17136116.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):650-65 [12951584.001]
  • (PMID = 20950443.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  • [Other-IDs] NLM/ PMC2972283
  •  go-up   go-down






Advertisement